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Bovine mastitis is one of the greatest challenges faced by dairy farmers worldwide. In the 
United States, one in four cows experience at least one case of clinical mastitis throughout the 
lactation. This disease creates an enormous economic burden due to decreased milk production, 
treatment costs, and premature culling. Mastitis is also an important animal welfare issue. The 
main objective of the research carried out during this doctorate was to generate knowledge to 
better understand and offer directions for the proper treatment of bovine mastitis. 
This dissertation comprises four research articles that are organized into two components: 
The applied portion of this research aimed to evaluate a novel method for diagnosis of mastitis 
pathogens and its’s suitability for use in the field (chapter two). Next, we assessed the potential 
of trace mineral supplementation in helping animals with subclinical mastitis resolve the disease 
(chapter three). The basic component of these doctoral studies employed molecular techniques to 
further understand the dynamics of mastitis and antimicrobial treatment in naturally infected 
animals (chapter four) and experimentally infected animals (chapter five). 
A novel chromogenic method for identification of mastitis-associated pathogens is 
suitable for use under field conditions. The color-based and straightforward interpretation allows 
 individuals with limited microbiology training to accurately diagnose the causative pathogen and 
provide basis for efficient selective antimicrobial therapy. Supplementation with trace minerals 
did not improve the overall cure of subclinical mastitis, nor decreased the overall incidence of 
clinical mastitis. However, we identified a tendency for improved subclinical mastitis cure in 
cows of third or greater lactation, and a decrease in the odds of having chronic clinical mastitis 
for primiparous cows. 
Longitudinal profiling of the milk microbiome revealed astonishing differences between 
healthy and mastitic milk. A significant reduction in microbial diversity was associated with 
disease in both naturally infected and experimentally challenged animals. Extended 
intramammary treatment with ceftiofur significantly decreased bacterial load, however such 
effect could only be observed during treatment administration. No differences on the microbial 
profile of mastitic or healthy milk due to antimicrobial treatment were observed. The capability 
of the milk microbiome to return to a healthy status in a relatively short period independent of 
intramammary antimicrobial therapy was observed consistently in both studies. The results 
observed here indicate that the milk harbors a resilient microbiome capable of restoring itself 
after mild and moderate cases of mastitis, independent of antimicrobial therapy. 
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CHAPTER 1 
INTRODUCTION 
Bovine clinical mastitis is a highly prevalent disease, and creates an incontestable 
economic burden in the dairy industry (Heikkila et al., 2012, Rollin et al., 2015, Taponen et al., 
2017). The main contributors to the cost of mastitis are decreased milk production, treatment 
costs, discarded milk, and premature culling (Cha et al., 2011, Heikkila et al., 2012, Rollin et al., 
2015). Most recent reports indicate that 24.8% of the United States’ dairy herd are affected with 
clinical mastitis (USDA, 2016), leading to the treatment of 21.7% of the US’ 9.3 million dairy 
cows with intramammary antimicrobials. It is not surprising that the vast majority of 
antimicrobials used in the dairy industry are associated with the treatment or prevention of 
mastitis (Pol and Ruegg, 2007, Gomes and Henriques, 2015). The overall objective of this 
doctoral research is to enrich the body of literature and provide evidence that can be used for 
better and more efficient management, treatment, and understanding of bovine mastitis.  
The etiology of bovine mastitis is complex. It is true that mammary infections caused by 
fungi, algae, and even viruses have been reported (Wellenberg et al., 2002, Dworecka-Kaszak et 
al., 2012, Ricchi et al., 2013); however, the vast majority of mastitis cases have been associated 
with bacteria (Hertl et al., 2014, Taponen et al., 2017). Due to the variety of pathogens that are 
causative of clinical mastitis, treatment based on knowledge of the organism responsible is an 
important practice, given that success of antimicrobial treatment is dependent on the pathogen 
involved (Royster and Wagner, 2015, Breen, 2016). On-farm culture allows for identification of 
mastitis pathogens as early as 24 hours after diagnosis of clinical mastitis, and became an 
invaluable tool (Royster et al., 2014, Viora et al., 2014). Equally important, studies have reported 
that selective antimicrobial therapy has the potential to decrease antibiotic usage by 50% without 
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significant differences in cow’s health or production traits (Lago et al., 2011a, b). Nevertheless, 
the accuracy of on-farm culture is highly variable between different observers (McCarron et al., 
2009a, b). On chapter two we evaluate a novel diagnostic tool for on-farm diagnosis of mastitis 
pathogens that is based on color. Chromogenic culture media has been employed in both human 
and animal samples (Perry and Freydiere, 2007, Kalchayanand et al., 2013) and allows rapid and 
accurate identification of specific pathogens. We compared the on farm use of Accumast®, a 
chromogenic based culture system, to results from the Cornell Quality Milk Production Services 
(QMPS) and molecular identification of cultured pathogens using 16S rRNA sequencing in two 
different studies. Results from these studies comprise the most applicable portion of this 
dissertation. 
In the same way as clinical mastitis, subclinical mastitis is also a prevalent disease and 
the lack of abnormal milk makes routine testing and identification of animals affected an 
important management practice in dairy farms. Subclinical mastitis has been associated with 
decreased milk production (Green et al., 2006, Boland et al., 2013), impaired animal welfare 
(Peters et al., 2015), increased risk of premature culling (Barlow et al., 2009), and decreased 
milk products yield (Ma et al., 2000, Mazal et al., 2007, Bobbo et al., 2017). Although certain 
intramammary antibiotics are currently labeled for the treatment of subclinical mastitis, evidence 
suggests that this practice is not cost-effective (Swinkels et al., 2005, Steeneveld et al., 2007).  
One possible alternative to reduce the impact of subclinical mastitis is ensuring adequate 
trace mineral availability. For instance, Selenium concentrations in blood have been associated 
with diminished intramammary infections, and low bulk tank somatic cell counts (Erskine et al., 
1987, Weiss et al., 1990, Kommisrud et al., 2005). Previous studies have also reported that 
injectable trace mineral supplementation can maintain elevated serum concentrations of copper, 
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selenium and zinc for two weeks after treatment (Bicalho et al., 2014), and that trace mineral 
supplementation during the transition period reduced the incidence of clinical mastitis and 
somatic cell count (Machado et al., 2013). In chapter 3 we hypothesized that injectable trace 
mineral supplementation had the potential to improve udder health of cows diagnosed with 
subclinical mastitis by restoring endogenous pools of these minerals, and we report results of a 
randomized clinical trial that evaluated the effect of a single injection of trace mineral 
supplementation on cure of subclinical mastitis, incidence of chronic clinical mastitis, and milk 
composition. 
In addition to the applied research conducted in chapters two and three, this dissertation 
delivers results from longitudinal profiling of the milk microbiome in chapters four and five. 
Extensive research has provided evidence that the milk harbors a plethora of bacteria, 
considerably larger than what can be observed using culture-dependent studies (Jost et al., 2013, 
Keane et al., 2013, Kuehn et al., 2013), highlighting the usefulness of molecular-based 
techniques on the investigation of mastitis (Oikonomou et al., 2012, Kuehn et al., 2013, Jimenez 
et al., 2015). Our objectives in chapter four were to apply state-of-the-art technologies to 
describe the microbiome of mastitic and healthy milk from ipsilateral quarters in animals 
naturally infected with a variety of mastitis pathogens and yielding negative results upon aerobic 
culture. Additionally, we evaluate the effect of third generation cephalosporins on cure of 
clinical mastitis. 
In chapter five we characterize the milk microbial profile before, during, and after 
experimental infection with Escherichia coli and subsequent treatment with a third generation 
cephalosporin. About 53% of dairy operations identify coliforms in mastitis cases, and ceftiofur, 
the only third generation cephalosporin labeled for veterinary use in the United States, accounts 
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for over 50% of treatments of mastitis (USDA, 2016). Amongst gram-negative pathogens, E. coli 
is the most common pathogen and accounts for as much as 80% of those cases of mastitis, 
especially in well managed dairy herds (Bradley et al., 2007). Nevertheless, the efficacy of 
antimicrobial treatment of E. coli mastitis is still ambiguously discussed. Investigators have 
reported improved bacteriological cure when animals affected with nonsevere cases of gram-
negative mastitis received extended intramammary treatment with a third generation 
cephalosporin (Schukken et al., 2011). On the other hand, after reviewing the available literature, 
Suojala (2013) recommends not treating animals affected with mild and moderate cases of E. 
coli mastitis (Suojala et al., 2013). Moreover, we assessed the effects of exposing the 
microbiome of healthy milk to ceftiofur. To date, no studies assessing the impact of these broad-
spectrum antibiotics on the healthy milk microbiota have been carried out. Intramammary 
administration of a broad-spectrum antimicrobial might favor the overgrowth of specific 
organisms and incite a shift in the microbial profile, similar to what has been previously reported 
in other niches (Chambers et al., 2015). The evidence gathered in this chapter offers information 
that can be used to substantiate the proper management of E. coli mastitis and further the 
understanding on the impact of third generation cephalosporins on the milk microbiome. 
In summary, the collection of studies that compose this dissertation explore a diagnostic 
tool for on-farm identification of pathogens associated with clinical mastitis, a non-antimicrobial 
alternative for the treatment of subclinical mastitis, and applies Next Generation Sequencing 
aiming to understand in depth the microbial dynamics of bovine clinical mastitis. The overall 
objective of the research conducted is to provide data that will facilitate effective management, 
treatment, and understanding of this disease. 
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ABSTRACT 
The present study aimed to evaluate an on-farm culture system for identification of milk 
pathogens associated with clinical mastitis in dairy cows using two different gold standard 
approaches: standard laboratory culture in study 1 and 16S rRNA sequencing in study 2. In study 
1, milk from mastitic quarters (i.e. presence of flakes, clots, or serous milk; n = 538) was 
cultured on-farm using a single plate containing three selective chromogenic media (Accumast® 
- FERA Animal Health LCC, Ithaca, NY) and in a reference laboratory using standard culture 
methods, which was considered the gold standard. In study 2, mastitic milk was cultured on-farm 
and analyzed through 16S rRNA sequencing (n = 214). In both studies, plates were cultured 
aerobically at 37oC for 24 h and read by a single technician masked to gold standard results. 
Accuracy, sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were 
calculated based on standard laboratory culture in study 1, and PPV was calculated based on 
sequencing results in study 2. Overall accuracy of Accumast® was 84.9%. Likewise, accuracy for 
identification of Gram-negative bacteria, Staphylococcus sp., and Streptococcus sp. was 96.4%, 
93.8%, and 91.5%, respectively. Sensitivity, specificity, PPV, and NPV were 75.0%, 97.9%, 
79.6%, and 97.3% for identification of E. coli, 100.0%, 99.8%, 87.5%, and 100.0% for S. aureus, 
70.0%, 95.0%, 45.7%, and 98.1% for other Staphylococcus sp., and 90.0%, 92.9%, 91.8%, and 
91.2% for Streptococcus sp. In study 2, Accumast® PPV was 96.7% for E. coli, 100.0% for 
Enterococcus sp., 100.0% for Other Gram-negatives, 88.2% for Staphylococcus sp., and 95.0% 
for Streptococcus sp., respectively. In conclusion, Accumast® is a unique approach for on-farm 
identification pathogens associated with mastitis, presenting overall sensitivity and specificity of 
82.3% and 89.9% respectively. 
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INTRODUCTION 
Clinical mastitis remains an important animal health issue and leads to major economic 
losses to the dairy industry worldwide. From 20% to 30% of dairy cows are diagnosed with 
clinical mastitis at least once during lactation (Sargeant et al., 1998, Hertl et al., 2014a). 
Estimated costs per case of clinical mastitis range between $179 and $488 depending upon milk 
prices, level of production in affected cows, culling policies, and stage of lactation when the 
disease occurred (Bar et al., 2008, Hagnestam-Nielsen and Ostergaard, 2009). In fact, treatment 
and prevention of mastitis are considered the most common causes of antibiotic use in dairy 
herds (Erskine et al., 2003, Pol and Ruegg, 2007). Although fungi and algae have been observed 
in the milk of cows diagnosed with clinical mastitis, inflammation of the mammary gland is 
caused predominantly by bacterial infections. Staphylococcus sp., Streptococcus sp., and 
coliforms account for approximately 90% of isolates in the milk of mastitic cows (Sargeant et al., 
1998, Olde Riekerink et al., 2008). Of particular importance for mastitis control programs, the 
success of antimicrobial therapy is dependent upon the causal pathogen associated with clinical 
mastitis. Intramammary antibiotic therapy improves the rate of cure in cows infected with 
coagulase-negative staphylococci, Staphylococcus sp., and environmental streptococci 
(Roberson, 2012). On the other hand, the use of an intramammary antibiotic is not recommended 
for cows with mastitis associated with E. coli (Suojala et al., 2013). Rapid on-farm identification 
of milk pathogens is critical for targeted antimicrobial therapy, which helps avoid the 
indiscriminate use of antibiotics in livestock and reduces the economic burden of clinical 
mastitis. 
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Several on-farm culture systems have been developed to characterize milk pathogens and 
substantiate the decision to treat cows with clinical mastitis. Initial on-farm culture systems were 
based on blood and MacConkey agar plates, which allowed for categorization of microorganisms 
into Gram-positive, Gram-negative, or no growth within 24 to 32 h and at relative low cost 
compared to the use of referral diagnostic laboratories. Previously published studies indicate that 
the use of selective treatment based on on-farm culture systems results has the potential to reduce 
antibiotic usage by 50% with no changes in the risk of disease recurrence, bacteriological cure, 
somatic cell count, milk production, and survival throughout lactation (Lago et al., 2011a, b). 
More sophisticated on-farm culture systems allow for further genus classification of Gram-
positive bacteria into Staphylococcus sp. and Streptococcus sp. and evaluation of Staphylococcus 
aureus presence in milk (Royster et al., 2014). Nevertheless, using these other techniques the 
assessment of colony appearance is required for detailed identification of milk pathogens and 
may reduce the predictive value of on-farm culture systems when conducted by farm personnel. 
In fact, the sensitivity of selective culture media to detect S. aureus in milk samples ranged from 
43.2% to 59.1% when plates were read by individuals with only limited microbiology training 
(McCarron et al., 2009a). 
Chromogenic media have been used for identification of microorganisms in both human 
and animal specimens (Perry and Freydiere, 2007, Kalchayanand et al., 2013). Chromogens 
incorporated in the culture media are cleaved by specific bacterial enzymes generating 
chromophores, which can be readily recognized with the naked-eye based on color change. The 
use of chromogenic culture media for identification of milk pathogens associated with mastitis 
has not been previously evaluated. However, this technology has the potential to increase the 
number of bacteria distinguishable using on-farm culture systems without requiring intensive 
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microbiology training by farm personnel. The main hypothesis of this study was that the use of 
chromogenic culture media allows for identification of milk pathogens associated with clinical 
mastitis in lactating dairy cows with satisfactory sensitivity and specificity. Therefore, specific 
objectives were to evaluate the use a of selective chromogenic on-farm culture system designed 
for identification of specific mastitis pathogens: staphylococci, streptococci, and Gram-negative 
bacteria, constituted by a single plate containing three selective chromogenic media (Accumast® 
- FERA Animal Health LCC, Ithaca, NY). Predictive values of this on-farm culture system were 
evaluated based on the results from an official diagnostic laboratory (study 1) and on through 
molecular identification of cultured pathogens using 16S rRNA sequencing (study 2) as gold 
standards. 
MATERIALS AND METHODS 
In-vitro Assessment of Colony Characteristics of Pure Bacterial Cultures Plated onto 
Chromogenic Media 
The assessment of growth of pure ATCC strains of pathogens previously described to be 
associated with bovine mastitis was performed in laboratory using Accumast® for the purpose of 
evaluation of the growth characteristics. The following Gram-positive and Gram-negative ATCC 
strains (Species, catalog number) were used in the evaluation: (Staphylococcus aureus, 25923; 
Staphylococcus epidermidis, 12228; Staphylococcus chromogenes, 43764; Streptococcus 
agalactiae, 27956; Streptococcus dysgalactiae, 43078; Streptococcus uberis, 700407; 
Enterococcus faecalis, 29212; Escherichia coli, 25922; Klebsiella oxytoca, 49131; Pseudomonas 
aeruginosa, 15442). Bacteria stocks were activated in unselective tryptic soy agar plates 
supplemented with 5% sheep blood and 0.1% esculin (BioMerieux, Durhan, NC). Plates were 
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incubated aerobically at 37oC for 24 h to ensure the presence of live bacteria and absence of 
contamination. For each strain, a single colony was transferred to 5 mL of brain heart infusion 
broth (Bacto Brain Heart Infusion; Becton, Dickinson and Company, Franklin Lakes, NJ), 
homogenized, and incubated overnight aerobically at 37oC. Bacterial cultures were diluted to 
1:1,000 in sterile PBS solution (Boston BioProducts, Ashland, MA). A sterile cotton swab was 
used to plate the diluted bacterial culture into each section of Accumast®, ensuring that the swab 
had been saturated in the bacterial sample between plating different sections of the plate. Plates 
were incubated aerobically at 37oC (Figure 2.1). 
The threshold selected for considering a sample positive for bacterial growth using the 
Accumast® culturing system was the presence of five or more colonies in a single section of the 
plate. Presence of bacterial growth in each of two different sections of the plate was considered a 
mixed infection and counted as positive for both types of bacteria. Presence of bacterial growth 
in each of three sections was considered contamination. 
Ethics Statement 
The present study was carried out in agreement with the recommendations of The Animal 
Welfare Act of 1966 (P.L. 89-544) and its amendments of 1970 (P.L. 91-579), 1976 (P.L. 94-
279), and 1985 (P.L. 99-1998) that regulates the transportation, purchase and treatment of 
animals used in research. The research protocol was reviewed and approved by the Institutional 
Animal Care and use Committee of the Cornell University (Protocol number: 2013-0056). 
Sampling animals that present abnormal milk during forestripping on milking preparation is also 
routine procedure at the study site. 
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Farm and Management 
On-farm evaluation of the use of Accumast® for identification of pathogens associated 
with clinical mastitis was performed in a single commercial dairy herd located in Venice Center, 
NY. During the study, approximately 2,800 cows were milked thrice daily in a double-52 
milking parlor and the yearly rolling herd average for milk yield was 13,800 kg, with an average 
bulk tank somatic cell count of 360.000 cells/mL. Primiparous and multiparous cows were 
housed separately in free-stall barns equipped with sprinklers, fans, and concrete stalls bedded 
with manure solids. Cows were fed a total mixed ration to meet or exceed the nutrient 
requirements of a 650 kg lactating Holstein cow producing 45 kg/d of milk with 3.5% fat and 
3.2% true protein when dry matter intake is 25 kg/d (NRC, 2001).  
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Sample Collection 
Clinical mastitis was defined as the presence of abnormal milk (i.e. presence of flakes, 
clots, or serous milk) during forestripping performed at the milking parlor. Milk from affected 
quarters was sampled aseptically by trained farm personnel following recommendations of the 
National Mastitis Council. Briefly, teats were cleaned and disinfected using 70% ethanol 
(vol/vol). The initial three streams were discarded and approximately 5 mL of milk was collected 
into a sterile plastic tube without preservative (Corning Life Sciences, Tewksbury, MA). Milk 
samples were kept refrigerated at 4 oC in a designated office adjacent to the milking parlor and 
plated at the farm no longer than 12 h after sample collection. 
On-farm Culture System 
The on-farm culture system evaluated here was created to allow for selective growth and 
identification of specific mastitis pathogens (i.e. staphylococci, streptococci, and Gram-negative 
bacteria), using a single plate containing three selective chromogenic media (Accumast®, FERA 
Animal Health LCC, Ithaca, NY). 
Milk samples were plated onto Accumast® using a sterile cotton swab. Before application 
into each of the three sections of Accumast® the swab was immersed in the milk sample. Plates 
were incubated at 37oC for 24 h and read on-farm by one of the investigators according to the 
flowchart provided for on-farm diagnosis of mastitis pathogens identifiable by Accumast® 
(Figure 2.2). Presence of bacterial growth, number of colonies, and color of colonies were 
recorded. Identification of milk pathogens was performed following instructions of the flowchart 
developed based on characteristics of growth of American Type Culture Collection (ATCC) 
strains described above. 
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Study 1: Identification of Milk Pathogens by Standard Laboratory Culture 
A total of 538 milk samples obtained from cows affected with clinical mastitis were 
collected as described above, from April to July, 2014. Immediately after collection and plating 
onto Accumast®, milk samples were refrigerated at 4oC and transported to the Quality Milk 
Production Services (QMPS) laboratory (Cornell University, Ithaca, NY) on ice. Milk samples 
were cultured following standard procedures for mastitis associated pathogens identification 
(NMC, 1999) and standard laboratory culture results were used as gold standard for evaluation of 
on-farm culture system. In summary, milk samples were plated onto trypticase soy agar plates 
supplemented with 5% of sheep blood and 0.1% esculin using a sterile cotton swab. Plates were 
incubated aerobically at 35oC to 38oC for at least 24 h but no longer than 48 h. Culture 
characteristics evaluated included size, color, hemolytic pattern, and odor. Ancillary tests for 
further bacterial classification included Gram stain and wet mount microscopic evaluations. 
Biochemical tests comprised evaluation of the presence of catalase using 3% hydrogen peroxide, 
coagulase using EDTA rabbit plasma tubes, indole using SpotTest (Hardy Diagnostics), KOH 
string test using 3% potassium hydroxide, oxidase, lactose, sorbitol fermentation, and CAMP 
tests. Additionally, surface carbohydrates group typing (BactiStaph and PathoDx, Thermo 
Scientific) and selective differential agars such as MacConkey, Edwards, and bile esculin were 
used when needed. Samples were considered mixed infections when two clearly distinct bacterial 
types in a well distributed growth pattern were detected, and both pathogens were reported. 
Identification of more than two distinct colony types and no contagious pathogens such as S. 
aureus or S. agalactiae present was considered contamination of the sample. Samples were 
considered negative when no aerobic bacterial growth was observed in the first 48 h of 
incubation following guidelines for accredited diagnostic laboratories.  
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Study 2: Identification of Milk Pathogens by 16S rRNA Sequencing 
To further evaluate the accuracy of Accumast® for on-farm identification of milk 
pathogens, a second study utilized bacterial 16S rRNA sequencing from pathogens isolated from 
mastitic milk samples cultured on-farm between October to December of 2014 using Accumast® 
plates as described above (n = 214) utilizing the Illumina platform.  
On-farm identification of milk pathogens was performed as previously described. Plates 
were read at the farm and those with bacterial growth were transported at room temperature to 
the laboratory for bacterial isolation, DNA extraction, and sequencing. For each sample, one 
colony was selected from Accumast®, collected using a sterile inoculating loop, and plated onto 
unselective tryptic soy agar plates supplemented with 5% sheep blood and 0.1% esculin 
(BioMerieux, Durhan, NC). Plates were incubated aerobically at 37oC for 24 h. This procedure 
was repeated twice using blood agar plates (Northeast Laboratory Services, Winslow, ME) to 
ensure that the colony isolated from Accumast® was free of contamination.  
Genomic DNA was isolated using InstaGene matrix (Bio-Rad laboratories, Hercules, 
CA) according to manufacturer’s recommendations. Concentration and purity of extracted DNA 
were evaluated based on optical density using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Rockland, DE). Amplification of the V4 hypervariable region of the 
bacterial 16S rRNA gene was performed from genomic DNA by PCR utilizing the primers 515F 
(AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCG
GTAA) and barcoded 806R (CAAGCAGAAGACGGCATACGAGATXXXXXXXXXXXX 
AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT) which have been optimized for the 
Illumina MiSeq platform (Caporaso et al., 2012). To allow for multiplex sample sequencing, 
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each sample was tagged with a unique 12-bp error-correcting Golay barcode for the 16S rRNA 
PCR selected using the earth microbiome project (http://www.earthmicrobiome.org/) as formerly 
described (Gilbert et al., 2010, Caporaso et al., 2012). Barcoded amplicons were generated in 
triplicate using 3 µL DNA template, 1X EconoTaq Plus Green Master Mix (Lucigen, Middleton, 
WI), and 5 µM of each primer. Thermocycler conditions were as follows: an initial denaturing 
step at 94°C for 3 min, 35 cycles of 94°C for 45 s, 50°C for 1 min, and 72°C for 90 s, and a final 
elongation step of 72°C for 10 min. Blank controls were incorporated in each reaction batch to 
ensure the absence of bacterial DNA contamination. Replicate amplicons were pooled and and 
visualized by electrophoresis through 1.2% (wt/vol) agarose gels stained with 0.5 mg/mL 
ethidium bromide. Purification of amplicons was performed using Gel PCR DNA Fragment 
Extraction kit (IBI Scientific, Peosta, IA). The NanoDrop ND-1000 spectrophotometer was used 
for quantification. 
Aliquots of 16S rRNA amplicons were standardized to the same concentration (i.e. 16 
ng/µL) and sequentially diluted to 20 pM following DNA denaturation. Because bacterial DNA 
was harvested from a single purified colony, amplicons were combined with 70% of PhiX 
(Illumina Inc., San Diego, CA). Amplicons were pooled into a single run and final equimolar 
library was sequenced using the MiSeq reagent kit V2 Nano for 300 cycles on the MiSeq 
platform (Illumina Inc., San Diego, CA). The 16S rRNA gene sequences were processed using 
the MiSeq Reporter analysis software version 2.5. Indexed reads were demultiplexed for 
generation of individual FASTQ files and reads were aligned to the Illumina-curated version of 
Greengenes database for genus-level classification of milk pathogens.  
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Statistical Analyses 
The predictive values of Accumast® for the identification of pathogens associated with 
mastitis were evaluated based on comparing Accumast® results with those from standard 
laboratory culture and results from 16S rRNA sequencing, which were considered the gold 
standards for comparison in study 1 and 2, respectively. Samples considered contaminated either 
by the reference laboratory (n = 3) or Accumast® (n = 6) were not included in the analysis. 
Results are presented as parameter estimates and 95% confidence intervals. Confidence intervals 
were calculated based on the standard error obtained from a binomial distribution following the 
formulas: SE=! !(!!!)!  and CI = estimate ± 1.96 × SE. 
Study 1: Standard Laboratory Culture as Gold Standard 
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) were calculated based on true positives, true negatives, false positives and false negatives 
as stated by (Dohoo I, 2009) comparing results from on-farm culture of milk samples collected 
between April and July 2014 and reference laboratory results using the same milk samples. In 
addition, accuracy was calculated by dividing the number of true positives and true negatives by 
the total number of tests. The simple Cohen's kappa coefficient (κ) was calculated using the 
FREQ procedure of SAS version 9.3 (SAS/STAT, SAS Institute Inc., Cary, NC). This parameter 
assumes that the two response variables (on-farm culture system and gold standard) are 
independent ratings, and the coefficient equals 1 when there is complete agreement between the 
two tests. The null hypothesis for this test is that if agreement happens due to chance the Kappa 
coefficient is equal to zero. Under this null hypothesis, P-values associated with this test equal or 
smaller than 0.05 were considered significant. 
 22 
 
Study 2: 16S rRNA Sequencing as Gold Standard 
Because only positive results from Accumast® plates were analyzed by 16S rRNA 
sequencing, the PPV and the simple Cohen's kappa coefficient between sequencing and 
Accumast® were assessed as previously described. Interpretation of Cohen's kappa coefficient 
was applied following description in (Dohoo I, 2009). A Kappa coefficient between 0.81 and 1.0 
corresponded to almost perfect agreement, 0.61 to 0.80 represented substantial agreement, an 
estimate between 0.41 and 0.60 was considered moderate agreement and a value of 0.21 to 0.40 
denoted fair agreements. 
RESULTS 
Study 1: Prevalence of Milk Pathogens Associated with Clinical Mastitis 
The prevalence reported herein was calculated based on results from standard laboratory 
culture which was considered the gold standard and is known as the true prevalence. The most 
prevalent pathogens in the milk of cows diagnosed with clinical mastitis according to results 
from QMPS standard laboratory culture were S. uberis, Streptococcus sp., and E. coli (Table 
2.1). Only a small proportion of quarters were diagnosed with mixed infections and 31.2% of 
milk samples did not result in growth of significant organisms. Three samples were characterized 
as contaminated by the reference laboratory and 6 samples were characterized as contaminated 
based on Accumast® and were excluded from subsequent analyses. Detailed information is 
provided in the supplementary tables 2.S1 and 2.S2. 
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Study 1: Test Characteristics of Accumast® Plates for Identification of Milk Pathogens 
Compared to Standard Laboratory Culture 
The overall sensitivity, specificity, PPV, NPV, accuracy, and κ coefficient of Accumast® 
for identification of mastitis associated pathogens are presented on (Table 2.2). Among the 
Gram-negative bacteria observed in milk samples, the sensitivity and PPV were smaller for the 
detection of other Gram-negatives compared with E. coli and Pseudomonas sp. (Table 2.3). The 
overall sensitivity, specificity, and accuracy for detection of Staphylococcus sp. were 78.4%, 
94.9%, and 93.8%, respectively (Table 2.4). Nevertheless, the accuracy for the identification of 
S. aureus was greater than for other Staphylococcus sp. Additionally, overall sensitivity, 
specificity and accuracy for identification of bacteria belonging to the streptococci group was 
high and the Cohen’s kappa coefficient among Accumast® and standard laboratory culture for 
this bacterial group was denoted substantial. 
Study 2: Test Characteristics of Accumast® Plates for Identification of Milk Pathogens 
Compared to 16S rRNA Gene Sequencing 
Results from 16S rRNA gene sequencing confirmed the precision of Accumast® plates 
for identification of milk pathogens associated with clinical mastitis in dairy cows (Table 2.5). 
Cohen’s kappa coefficient was above 85% for all bacterial groups evaluated. Likewise, PPV was 
above 88% across all groups.  
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Table 2.1. Prevalence of pathogens associated with clinical mastitis. 
Bacteria identified by laboratory culture1 Number Prevalence, % 
Streptococcus uberis 134 24.9 
Streptococcus sp. 56 10.4 
Escherichia coli 49 9.1 
Streptococcus dysgalactiae 40 7.8 
Staphylococcus sp. 28 5.2 
Klebsiella sp. 16 3.0 
Mixed infection 14 2.2 
Trueperella pyogenes 10 1.9 
Staphylococcus aureus 7 1.3 
Enterococcus sp. 7 1.3 
Gram-negative bacilli 5 0.9 
Pseudomonas sp. 1 0.2 
No growth 168 31.2 
Contamination 3 0.6 
Total 538 100 
1Results from standard laboratory culture performed by the Quality Milk Production Services 
laboratory at Cornell University (Ithaca, NY). 
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Table 2.2. Overall test characteristics of selective chromogenic culture plates to identify bacteria 
associated with clinical mastitis determined by standard laboratory culture. 
Parameter Accumast® 95% Confidence Interval 
Number of Tests 529  
True Prevalence, % (n/n) 66.2 (350/529) (66.0 – 66.3) 
Sensitivity, % 82.3 (82.1 – 82.5) 
Specificity, % 89.9 (89.6 – 90.3) 
PPV1, % 94.1 (94.0 – 94.3) 
NPV2, % 72.2 (71.8 – 72.6) 
Accuracy, % 84.9 (84.7 – 85.0) 
κ 3, % 0.68 (0.61 – 0.74) 
κ P-value  <0.0001  
Each milk sample was cultured for identification of bacteria associated with clinical mastitis and 
culture results from the reference laboratory were considered the gold standard. Each plate was 
capable of identifying Gram-negative bacteria (E. coli, Pseudomonas sp., and other Gram-
negatives), Staphylococcus sp. (S. aureus and Staphylococcus sp.), and Streptococcus sp. Only 
sections with more than five colonies were considered positive. Samples considered 
contaminated in either standard culture (n = 3) or on-farm culture (n = 6) were not included in 
the analysis (n = 9). Plates with no bacterial growth (n = 168) were considered in all calculations. 
1 Positive predictive value. 
2 Negative predictive value. 
3 Cohen’s kappa coefficient. κ ≤ 0 denotes poor agreement; 0.01 to 0.20 denotes slight 
agreement; 0.21 to 0.40 denotes fair agreement; 0.41 to 0.60 denotes moderate agreement; 0.61 
to 0.80 denotes substantial agreement and 0.81 to 1.00 denotes almost perfect agreement. 
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 T
able 2.3. Test characteristics of A
ccum
ast ®
 plates to identify G
ram
-negative bacteria associated w
ith clinical m
astitis determ
ined by 
standard laboratory culture. 
 
Plate results 
Param
eter 
O
verall G
ram
-negative 
E. coli 
Pseudom
onas sp. 
O
ther G
ram
-negatives 
True Prevalence, %
 (C
I 1) n/n 
14.4 (14.2 – 14.5) 76/529 
9.8 (9.7 – 9.9) 52/529 
0.2 (0.2 – 0.2) 1/529 
4.3 (4.3 – 4.4) 23/529 
Sensitivity, %
 (C
I) 
81.6 (80.6 – 82.6) 
75.0 (73.4 – 76.6) 
100.0 (100.0 – 100.0) 
52.2 (47.9 – 56.4) 
Specificity, %
 (C
I) 
98.9 (98.9 – 98.9) 
97.9 (97.8 – 98.0) 
99.8 (99.8 – 99.8) 
99.2 (99.2 – 99.2) 
PPV
2, %
 (C
I) 
92.5 (91.8 – 93.3) 
79.6 (78.0 – 81.2) 
50.0 (1.0 – 99.0) 
75.0 (69.7 – 80.3) 
N
PV
3, %
 (C
I) 
97.0 (96.9 – 97.0) 
97.3 (97.2 – 97.4) 
100.0 (100.0 – 100.0) 
97.9 (97.8 – 97.9) 
A
ccuracy, %
 (C
I) 
96.4 (96.3 – 96.5) 
95.7 (95.6 – 95.7) 
99.8 (99.8 – 99.8) 
97.2 (97.1 – 97.2) 
κ
4, %
 (C
I) 
0.84 (0.77 – 0.91) 
0.74 (0.65 – 0.84) 
0.66 (0.04 – 1.0) 
0.60 (0.41 – 0.78) 
κ
 P-value  
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Each m
ilk sam
ple w
as cultured for identification of bacteria associated w
ith clinical m
astitis and culture results from
 the reference 
laboratory w
ere considered the gold standard. O
nly sections w
ith m
ore than five colonies w
ere considered positive. Sam
ples 
considered contam
inated in either standard culture (n = 3) or on-farm
 culture (n = 6) w
ere not included in the analysis (n = 9). Plates 
w
ith no bacterial grow
th (n = 168) w
ere considered in all colum
ns. Pure and m
ixed cultures w
ith the species of interest w
ere 
com
bined. G
row
th on G
ram
-negative section regardless of color of colonies w
as considered positive for overall calculations. O
nly 
correct identification of bacterial group based on color w
as considered positive for w
ithin group calculations. 
1 95%
 confidence interval. 
2 Positive predictive value. 
3 N
egative predictive value. 
4 C
ohen’s kappa coefficient. κ ≤ 0 denotes poor agreem
ent; 0.01 to 0.20 denotes slight agreem
ent; 0.21 to 0.40 denotes fair agreem
ent; 
0.41 to 0.60 denotes m
oderate agreem
ent; 0.61 to 0.80 denotes substantial agreem
ent and 0.81 to 1.00 denotes alm
ost perfect 
agreem
ent. 
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 T
able 2.4. Test characteristics of A
ccum
ast ®
 to identify G
ram
-positive bacteria associated w
ith clinical m
astitis determ
ined by 
standard laboratory culture. 
 
Plate results 
Param
eter 
O
verall G
ram
-positive 
Streptococcus 
O
verall G
ram
-
positive 
Staphylococcus 
S. aureus 
Staphylococcus sp. 
True Prevalence, %
 (C
I 1) n/n 
47.1 (46.9 – 47.3) 249/529 
7.0 (6.9 – 7.1) 37/529 
1.3 (1.3 – 1.4) 7/529 
5.7 (5.6 – 5.8) 30/529 
Sensitivity, %
 (C
I) 
90.0 (89.7 – 92.7) 
78.4 (76.2 – 80.6) 
100.0 (100.0 – 100.0) 
70.0 (67.0 – 73.0) 
Specificity, %
 (C
I) 
92.9 (92.7 – 93.0) 
94.9 (94.8 – 95.0) 
99.8 (99.8 – 99.8) 
95.0 (94.9 – 95.1) 
PPV
2, %
 (C
I) 
91.8 (91.6 – 92.0) 
53.7 (51.9 – 55.5) 
87.5 (79.4 – 95.6) 
45.7 (43.5 – 47.8) 
N
PV
3, %
 (C
I) 
91.2 (91.0 – 91.4) 
98.3 (98.3 – 98.4) 
100.0 (100.0 – 100.0) 
98.1 (98.1 – 98.2) 
A
ccuracy, %
 (C
I) 
91.5 (91.4 – 91.6) 
93.8 (93.7 – 93.9) 
99.8 (99.8 – 99.8) 
93.6 (93.5 – 93.7) 
κ
4, %
 (C
I) 
0.82 (0.78 – 0.87) 
0.60 (0.48 – 0.72) 
0.93 (0.80 – 1.00) 
0.52 (0.37 – 0.66) 
κ
 P-value  
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Each m
ilk sam
ple w
as cultured for identification of bacteria associated w
ith clinical m
astitis and culture results from
 the reference 
laboratory w
ere considered the gold standard. O
nly sections w
ith m
ore than five colonies w
ere considered positive. Sam
ples 
considered contam
inated in either standard culture (n = 3) or on-farm
 culture (n = 6) w
ere not included in the analysis (n = 9). Plates 
w
ith no bacterial grow
th (n = 168) w
ere considered in all colum
ns. Pure and m
ixed cultures w
ith the species of interest w
ere 
com
bined. G
row
th on G
ram
-positive section regardless of color of colonies w
as considered positive for overall calculations. O
nly 
correct identification of bacterial group based on color w
as considered positive for w
ithin group calculations. 
1 95%
 confidence interval. 
2 Positive predictive value. 
3 N
egative predictive value. 
4 C
ohen’s kappa coefficient. κ ≤ 0 denotes poor agreem
ent; 0.01 to 0.20 denotes slight agreem
ent; 0.21 to 0.40 denotes fair agreem
ent; 
0.41 to 0.60 denotes m
oderate agreem
ent; 0.61 to 0.80 denotes substantial agreem
ent and 0.81 to 1.00 denotes alm
ost perfect 
agreem
ent. 
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Table 2.5. Test characteristics Accumast® plates to identify bacteria associated with clinical 
mastitis determined by 16S rRNA sequencing. 
 Parameter 
Bacterial group Tests, (n/n) PPV1, % (CI2) κ 3, % κ P-value 
Overall 214 95.3 (95.1 – 95.5) 0.89 (0.83 – 0.95) <0.0001 
Escherichia 30/214 96.7 (95.5 – 97.8) 0.85 (0.76 – 0.95) <0.0001 
Enterococcus 3/214 100.0 (100.0 – 100.0) 1.000 (1.0 – 1.00) <0.0001 
Other Gram-negatives 23/214 100.0 (100.0 – 100.0) 0.95 (0.88 –1.00) <0.0001 
Staphylococcus 17/214 88.2 (84.5 – 91.9) 0.93 (0.83 – 1.00) <0.0001 
Streptococcus 141/214 95.0 (94.7 – 95.3) 0.91 (0.86 – 0.97) <0.0001 
Isolates from cases of clinical mastitis cultured using Accumast® plates from October 2014 to 
December 2014 were subjected to 16S rRNA gene sequencing for genus level determination of 
bacterial growth. Only positive results were available for comparison, therefore only PPV and 
the Cohen’s kappa coefficient between 16S rRNA sequencing and Accumast® were calculated.  
1 Positive predictive value. 
2 95% confidence interval. 
3 Cohen’s kappa coefficient. κ ≤ 0 denotes poor agreement; 0.01 to 0.20 denotes slight 
agreement; 0.21 to 0.40 denotes fair agreement; 0.41 to 0.60 denotes moderate agreement; 0.61 
to 0.80 denotes substantial agreement and 0.81 to 1.00 denotes almost perfect agreement. 
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Figure 2.1. Visual assessment of Gram-positive and Gram-negative bacterial growth on 
Accumast® plates performed in laboratory. Pictures were taken onto dark background. Plate 
without bacteria (panel A), Staphylococcus aureus (panel B), Staphylococcus epidermidis (panel 
C), Staphylococcus chromogenes (panel D), Streptococcus agalactiae (panel E), Streptococcus 
dysgalactiae (panel F), Streptococcus uberis (panel G), Enterococcus faecalis (panel H) 
Escherichia coli (panel I)*, Klebsiella oxytoca (panel J)*, and Pseudomonas aeruginosa (panel 
K). *Pictures were taken onto light background. 
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Figure 2.2. Flow-chart for on-farm diagnosis of mastitis pathogens based on Accumast®. 
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DISCUSSION 
Knowing the etiology of mammary infections is extremely valuable for the development 
of strategies to control mastitis (Cha et al., 2014). Selective treatment of cows diagnosed with 
clinical mastitis present major advantages to dairy herds including smaller costs associated with 
antimicrobials, reduction in the number of animals managed in the hospital pen, less discarded 
milk, and a potential reduction in the rate of development of antibiotic resistance in livestock 
(Lago et al., 2011a, Oliver and Murinda, 2012). Targeted therapy relies on rapid and accurate 
identification of milk pathogens (McDougall et al., 2007, Cha et al., 2014, Hertl et al., 2014a, 
Royster and Wagner, 2015). The on-farm culture system evaluated in this study was designed to 
enable farm personnel to identify major bacteria associated with clinical mastitis in dairy cows in 
a straightforward manner. The spectrum of microorganisms identifiable using Accumast® 
encompasses both Gram-positive (i.e. streptococci, staphylococci, and S. aureus) and Gram-
negative pathogens (i.e. E. coli, Pseudomonas sp. and other Gram-negative pathogens). These 
bacteria have been reported to represent 80% and 100% of all milk pathogens isolated from 
mastitic cows in the states of New York (Hertl et al., 2014b) and Wisconsin (Oliveira and Ruegg, 
2014). When compared to a referral laboratory, the overall accuracy of Accumast® to identify 
milk pathogens was 84.9%; with individual accuracies of 96.4%, 93.8%, and 91.5% for Gram-
negative bacteria, staphylococci, and streptococci, respectively. Additionally, when compared to 
16S rRNA sequencing results, the overall positive predictive value of Accumast® was 95.3% and 
the Cohen's kappa coefficient was 0.89, which according to (Dohoo I, 2009), is considered 
almost perfect agreement. The present results support the use of this culture system for on-farm 
identification of pathogens associated with clinical mastitis, for decision making in targeted 
treatment protocols, and for pathogen prevalence surveillance. It is important to acknowledge 
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that certain pathogens were present in very low prevalence in our study (e. g. S. aureus) and 
further research should be conducted to validate current findings. 
Major advances in the control of contagious pathogens implicated in mastitis have been 
accomplished through improvement of milking hygiene and management practices (Bushnell, 
1984, Hogan et al., 1989, Hillerton and Berry, 2003). However, mammary infections with S. 
aureus remain a concern in dairy herds and require constant surveillance, aggressive antibiotic 
therapy, and segregation or culling of infected cows (Zecconi et al., 2005, Boss et al., 2011). On-
farm culture systems have been used successfully to characterize bacteria present in the milk of 
mastitic cows as Gram-positive, Gram-negative, or no growth after 24 h to 32 h of incubation. 
Nonetheless, inconsistent results were observed when classification at the genus and/or species 
level was attempted by readers lacking extensive microbiology training. For instance, the 
sensitivity and specificity of University of Minnesota Triplate for identification of S. aureus by 
four readers with limited microbiology training ranged from 43.2% to 59.1% and 93.8% to 
95.9%, respectively (McCarron et al., 2009a). In another study in which two readers without 
extensive microbiology training used the same system to identify S. aureus, sensitivity ranged 
from 52% to 78% and specificity from 92% to 98% (Royster et al., 2014). Likewise, other 
investigators used a different triplate for identification of Gram-negative bacteria, staphylococci, 
and other Gram-positive bacteria and achieved sensitivity and specificity for identification of S. 
aureus of 65% and 94% (Viora et al., 2014). In the present study, the use of Accumast® resulted 
in sensitivity and specificity of 100% and 99.8% for identification of S. aureus under field 
conditions when compared to standard laboratory culture. These results were confirmed by our in 
vitro studies, in which ATCC strains of S. aureus, S. chromogenes, and S. epidermidis were 
plated in all sections of the Accumast® plate and the growth of S. aureus colonies were of pink 
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coloration and markedly different from the other two species of staphylococci. The high 
predictive value of this system compared with other on-farm culture systems can be partially 
explained by the clear difference in color between S. aureus and other staphylococci in 
Accumast®, as opposed to the need of identification of more subtle differences in colony 
characteristics and β-hemolysis in other methods (McCarron et al., 2009a). In fact, hemolysin 
production by S. aureus has been shown to be variable (Boerlin et al., 2003). It is important to 
acknowledge that this particular species comprised only 1.3% of the pathogen prevalence in the 
study sample and further research is needed to confirm the findings presented here. Additionally, 
when compared to 16S rRNA, Accumast® presented PPV and a Cohen's kappa coefficient of 
0.89, considered almost perfect agreement (Dohoo I, 2009) for all bacterial groups evaluated. 
Unfortunately the use of this technique as the gold standard does not allow for calculation of 
NPV, Sensitivity and Specificity, since only positive results from the test being evaluated are 
available for comparison. However, as mentioned before, bacterial characteristics often used for 
species identification such as hemolysin production have been shown to be variable. This 
inconsistency is not an issue when targeted sequencing of the 16S rRNA gene is performed, once 
this gene has been proved to be highly conserved among different phenotypes of the same 
bacterial species.  
The specificity and NPV of Accumast® for identification of Staphylococcus sp. were 
above 95%; however, its sensitivity and PPV were much smaller compared to that of S. aureus, 
which can be a limitation of the on-farm culture system evaluated here. Similarly, previous 
reports also observed a reduced sensitivity for discrimination between S. aureus and other 
staphylococci (McCarron et al., 2009a, Royster et al., 2014). Although not ideal, the reduced 
capacity of on-farm culture system to identify other Staphylococcus sp. has a smaller impact on 
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its applicability in dairy herds when compared to the capacity of correctly identifying S. aureus. 
Coagulase-negative staphylococci (CNS) are considered pathogens of minor importance 
compared with other bacteria while S. aureus remain a major concern because of its contagious 
behavior (Pyorala and Taponen, 2009, Boss et al., 2016, da Costa et al., 2016). In fact, CNS has 
been associated with subclinical or moderate clinical mastitis and with high spontaneous cure 
rates (McDougall, 1998, Wilson et al., 1999, Taponen et al., 2006, Tomazi et al., 2015). Other 
studies argue that CNS are the main species responsible for mammary gland infection in 
ruminants, causing significant changes in milk metabolites that play an important role in the 
quality of dairy products (Silanikove et al., 2014a, b). Regardless of the effect of CNS in 
mammary infections, milk yield, and downstream milk quality, we acknowledge that 
improvement on the capability of correctly diagnosing Staphylococcus sp. would be 
advantageous for the on-farm culture system presented here. 
Environmental streptococci were the most prevalent bacteria isolated in the present study, 
which is in agreement with previous studies (Olde Riekerink et al., 2008, McCarron et al., 2009a, 
b, Oliveira and Ruegg, 2014). Among environmental pathogens, S. uberis plays an important role 
in intramammary infections because of its invasive comportment and association with recurring 
infections (Hillerton and Berry, 2003, McDougall et al., 2007, Abureema et al., 2014). The 
ability to identify cows infected with Streptococcus sp. is critical for health management in dairy 
herds as these infections respond well to commercially available intramammary antimicrobials 
(Roberson, 2012). The use of Accumast® resulted in high overall sensitivity and specificity for 
identification of environmental streptococci independent of the species characterized by standard 
laboratory culture. The sensitivity and overall accuracy of Accumast® plates for identification of 
Streptococcus sp. were comparable to the ones reported for the methods evaluated by McCarron 
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et al. (2009) and Royster et al. (2014). Although the differentiation among Streptococcus species 
using Accumast® was not attempted, visual inspection of ATCC cultures indicate a lighter blue 
associated with S. agalactiae and S. dysgalactiae compared with that of S. uberis. Similar 
patterns were also observed during the field study; however, such nuances in tonality were not 
recorded and further research is necessary to evaluate the predictive values of Accumast® for 
differentiation of Streptococcus sp. in the species level. 
Bovine mastitis associated with E. coli has been reported to have high self-cure rates. In 
an elegant review, Suojala et al., (2013) compiled data from studies that evaluated the treatment 
of E. coli caused bovine mastitis and concluded that intramammary antibiotic therapy should not 
be recommended in mild and moderate cases. For this reason, identifying mastitic cows infected 
primarily with E. coli is a critical step towards reducing the use of antibiotics in dairy herds. On 
the other hand, results reported by Schukken et al., (2011) support the use of intramammary 
antimicrobials for treatment of mild and moderate cases of Gram-negative mastitis. In that study, 
a randomized clinical trial was conducted and revealed a significant increase in the odds of 
clinical and bacteriological cure in treated animals when compared to non-treated controls. The 
accuracy of Accumast® to identify E. coli was 95.7% compared with standard laboratory culture, 
with sensitivity and specificity of 75.0% and 97.9%, respectively which are greater than the 
results from Viora et al. that reported a sensitivity and specificity of 67% and 92% for 
identification of E. coli in the milk of mastitic cows using a triplate containing selective culture 
media. Nevertheless, the use of systemic antimicrobial therapy combined with support therapy 
and anti-inflammatory drugs are recommended in severe cases of E. coli mastitis due to the high 
indices of bacteremia experienced in cows undergoing this presentation of the disease (Wenz et 
al., 2001, Erskine et al., 2002). 
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CONCLUSIONS 
The on-farm culture system evaluated in the present study is suitable for use under field 
conditions and presented substantial overall accuracy for detection of common mastitis 
pathogens, which was confirmed by 16S rRNA gene sequencing. Accumast® provides a unique 
approach for on-farm identification of mastitis associated pathogens, mostly through its 
straightforward color-based classification of bacteria. Identification of bacteria based on color 
allows for easy interpretation by individuals with limited microbiological training; thus, 
providing the basis for selective antimicrobial therapy of mastitic cows based on causal 
microorganisms. Further research is warranted to evaluate test characteristics of Accumast® 
between multiple study sites with distinct mastitis pathogens prevalence profiles and among 
readers without microbiology experience. 
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SUPPLEMENTARY INFORMATION 
Table 2.S1. Results from Study 1: Standard laboratory culture was considered the gold standard 
Accumast result False Negatives 
False 
Positives 
True 
Negatives 
True 
Positives 
E. coli 4 2 0 23 
E. coli, Staphylococcus 0 0 0 2 
E. coli, Streptococcus 1 0 0 17 
Enterococcus 1 0 0 0 
Enterococcus, Staphylococcus 1 0 0 0 
Negative 42 0 160 0 
Other Gram- 1 1 0 9 
Other Gram-, Staphylococcus 0 0 0 1 
Other Gram-, Streptococcus 0 0 0 4 
Staphylococcus 3 9 0 18 
Pseudomonas 1 0 0 1 
S. aureus 0 1 0 7 
Streptococcus 8 5 1 194 
Streptococcus, Staphylococcus 0 0 0 12 
Total 62 18 161 288 
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ABSTRACT 
Objectives of this clinical trial were to evaluate the effects of injectable trace mineral 
supplementation (ITMS) on somatic cell count (SCC), linear score (LS), milk yield, milk fat and 
protein contents, subclinical mastitis cure, and incidence of clinical mastitis in cows with 
elevated SCC. Holstein cows from a commercial dairy farm in New York were evaluated for 
subclinical mastitis, defined as SCC ≥ 200 × 103 cells/mL on the test day preceding enrollment. 
Cows with a history of treatment for clinical mastitis in the current lactation and those pregnant 
for more than 150 d were not eligible for enrollment. Cows fitting inclusion criteria were 
randomly allocated to one of two treatment groups. Cows assigned to ITMS (n = 306) received 
one subcutaneous injection containing zinc (300 mg), manganese (50 mg), selenium (25 mg), 
and copper (75 mg) at enrollment (d 0). Control cows (CTRL; n = 314) received one 
subcutaneous injection of sterile saline solution. Following treatment, visual assessment of milk 
was performed daily and cows with abnormal milk (i.e. presence of flakes, clots, or serous milk) 
were diagnosed with clinical mastitis (CM). Chronic clinical mastitis (CCM) was defined as 
cows with three or more cases of CM. Milk yield, milk fat and protein contents, SCC, and LS 
were evaluated once monthly. Additionally, randomly selected animals were sampled to test 
serum concentrations of selected minerals on d 0 and d 30 (n = 30 cows/treatment). Treatment 
did not affect serum concentrations of calcium, magnesium, phosphorus, potassium, copper, iron, 
manganese, selenium, and zinc on d 30. Injectable supplementation with trace minerals did not 
improve overall cure of subclinical mastitis (CTRL = 42.8 vs. ITMS = 46.5%), although a 
tendency was observed in cows with three or more lactations (CTRL = 27.1 vs. ITMS = 40.0%). 
Supplementation did not reduce treatment incidence of CM (CTRL = 48.2 vs. ITMS = 41.7%); 
however, it tended to reduce the proportion of cows diagnosed with CCM (CTRL = 16.9 vs. 
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ITMS = 12.0%) particularly among first lactation cows (CTRL = 18.4 vs. ITMS = 7.6%). Cure 
of subclinical mastitis was associated with higher serum concentrations of phosphorus and 
selenium on d 30. Supplementing trace minerals to cows with elevated SCC had no effect on 
milk yield, milk fat and protein contents, SCC, and LS.  
Keywords: mastitis, udder health, zinc, manganese, selenium, copper 
 
INTRODUCTION 
Mastitis remains a highly prevalent disease in dairy herds and leads to major economic 
losses to the dairy industry worldwide, with each clinical case being estimated to cost between 
$179 and $488 (Bar et al., 2008, Hagnestam-Nielsen and Ostergaard, 2009). Despite the absence 
of clinical signs and visible changes in milk, subclinical mastitis, commonly diagnosed through 
an increase in somatic cell count (SCC), is also extremely costly to dairy herds. Cows with 
subclinical mastitis produce up to 4.6 kg/d less milk compared with healthy herdmates (Green et 
al., 2006, Halasa et al., 2009, Boland et al., 2013), represent a reservoir of infection for other 
cows in the herd (White et al., 2006) and are at a greater risk of being culled or developing 
clinical mastitis (Deluyker et al., 1993, Barlow et al., 2009).  
Ensuring adequate trace mineral availability is a potential strategy to reduce the impact of 
high SCC. Trace minerals are critical for proper immune response and play an important role in 
udder health. Selenium is a component of the antioxidant enzyme glutathione peroxidase and 
selenium-deficient dairy cows have impaired neutrophil function in blood (Hogan et al., 1990) 
and milk (Grasso et al., 1990). Elevated concentrations of selenium in blood are associated with 
reduced prevalence of intramammary infection and reduced bulk tank SCC (Erskine et al., 1987, 
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Weiss et al., 1990, Kommisrud et al., 2005). Additionally, copper and zinc are essential for 
bovine superoxide dismutases, enzymes responsible for catalyzing superoxide radicals into 
oxygen and hydrogen peroxide. Dietary copper has been associated with neutrophil killing 
activity in dairy cattle (Torre et al., 1996). Dairy heifers fed peripartum diets supplemented with 
copper had lower bacterial counts and SCCs in milk following an intramammary challenge with 
E. coli compared with counterparts fed a diet with marginal copper content (Scaletti et al., 2003). 
Although diets formulated to meet the NRC recommendations are expected to provide 
adequate amounts of trace minerals, nutrient interactions within the rumen, reduced appetite, 
restricted access to the feed bunk, and absorptive disorders might limit their intake or 
bioavailability. Conversely, two subcutaneous injections of a mineral solution in prepartum dairy 
cows sustained elevated serum concentrations of copper, selenium and zinc for approximately 14 
d following the last treatment (Bicalho et al., 2014). Interestingly, cows diagnosed with metritis 
had lower selenium and zinc concentrations in serum during early postpartum compared with 
healthy herdmates (Bicalho et al., 2014). Previous results indicate that the use of the same 
injectable trace mineral supplementation during the transition period improved udder health in 
dairy cows. Supplementation performed at 230 and 260 d of gestation and at 35 DIM reduced the 
incidence of clinical mastitis and SCC in multiparous cows (Machado et al., 2013). These results 
suggest that cows undergoing stress caused by infectious diseases have lower levels of selenium 
and zinc, and that restoring endogenous pools might be associated with cure. The effects of 
injectable trace minerals in cows previously diagnosed with subclinical mastitis remains to be 
determined. For that reason, determining to what extent each mineral is affected in cows with 
elevated SCC and whether or not increasing circulating concentrations of trace minerals is 
 48 
 
associated with reduction of SCC is expected to provide valuable information for the treatment 
of subclinical mastitis. 
The hypothesis of the present study was that injectable trace mineral supplementation 
would improve udder health in dairy cows diagnosed with subclinical mastitis. Objectives were: 
1) to evaluate the effects of an injectable trace mineral supplementation containing selenium, 
copper, zinc, and manganese on SCC, linear score (LS), milk yield and composition, incidence 
of clinical mastitis, and subclinical mastitis cure in cows previously diagnosed with subclinical 
mastitis and 2) to investigate the extent in which minerals are affected in dairy cows with 
elevated SCC.  
MATERIALS AND METHODS 
Animal Care Statement 
The experimental procedures were carried out according to the research protocol 2013-
0056, that was reviewed and approved by the Institutional Animal Care and use Committee of 
the Cornell University. 
Farm and Management 
This study was conducted on a single commercial dairy farm located in upstate New 
York. During the experimental period, the farm milked approximately 3,000 cows. In total, 620 
Holstein cows were enrolled in the study from January 10th to April 8th, 2014. Primiparous and 
multiparous cows were housed separately in free-stall barns with concrete stalls covered with 
mattresses and bedded with manure solids. Cows were fed a total mixed ration to meet or exceed 
the nutrient requirements of a 650 kg lactating Holstein cow producing 45 kg/d of milk with 
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3.5% fat and 3.2% true protein when DMI is 25 kg/d (NRC, 2001). Fifteen feed samples were 
collected at the feed bunk, pooled, and submitted for analysis at the DairyOne Laboratory 
(DairyOne Laboratories, Ithaca, NY). Diet composition is presented in (Table 3.1). Cows were 
milked thrice daily in a double-52 milking parlor. The farm participated on DHIA and all 
lactating cows were tested for SCC and milk composition once monthly.  
Enrollment Criteria and Case Definitions 
Lactating dairy cows that had SCC ≥ 200 × 103 cells/mL in the closest DHIA test to 
enrollment, were less than 150 d pregnant, and had not received intramammary antibiotic therapy 
in the current lactation were eligible for enrollment. Milk sampling was performed by DHIA 
personnel and assayed using flow cytometry (DairyOne Laboratories, Ithaca, NY). Subclinical 
mastitis was defined as SCC ≥ 200 × 103 cells/mL and subclinical mastitis cure was defined for 
cows with SCC < 200 × 103 cells/mL on the first monthly DHIA test following enrollment. 
Clinical mastitis was defined based on visual evaluation of milk in a forestripping test performed 
every milking by trained farm personnel. Cows with presence of flakes, clots, or serous milk 
were diagnosed with clinical mastitis independent of systemic illness and signs of inflammation 
in the mammary gland. Cows diagnosed with clinical mastitis were moved to the hospital pen 
and treated according to the study site’s standard procedures. Chronic clinical mastitis was 
defined as cows with three or more cases of clinical mastitis after enrollment.  
Experimental Design and Treatments 
This study was conducted as a complete randomized design and cows were enrolled on a 
monthly basis. A total of 620 cows were included in the study, from which 240 (38.7%) were in 
the first lactation, 215 (34.7%) were in the second lactation, and 165 (26.6%) were in the third or 
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later lactations. Cows diagnosed with subclinical mastitis were randomly allocated into one of 
two treatments based on a list generated using the RAND function of Excel (Microsoft, 
Redmond, WA). On the day of enrollment, henceforth defined as study d 0, cows assigned to 
receive injectable trace mineral supplementation (ITMS; n = 306) were treated once 
subcutaneously in the ischiorectal fossa with 5ml of an injectable trace mineral solution 
containing zinc (300 mg), manganese (50 mg), selenium (25 mg), and copper (75 mg) (Multimin 
90, Multimin North America Inc., Fort Collins, CO). Cows assigned to the control group 
(CTRL; n = 314) received a subcutaneous injection of sterile saline solution of the same volume 
(5 mL). 
Sampling and Data Collection 
Blood samples were collected from a randomly selected subset of cows (n = 
30/treatment) before injection of trace mineral supplementation on d 0 and again on d 30 for the 
analysis of mineral concentrations. Blood was sampled by puncture of coccygeal vessels into 
evacuated tubes without anticoagulant (Becton Dickinson, Franklin Lakes, NJ). Blood tubes 
were placed on ice and centrifuged at 2,000 x g for 15 min for serum separation within 5 h of 
collection. Serum samples were frozen at -80ºC until assayed. 
Individual milk production was measured using on-farm milk meters (ALPRO, DeLaval, 
Tumba, Sweden) once monthly during the DHIA test day. Milk fat and protein contents were 
measured using Fourier transform infrared spectroscopy (MilkoScan, Eden Prairie, MN). 
Somatic cell counts were determined by flow cytometry (Fossomatic FC, Eden Prairie, MN). 
Linear scores were calculated based on SCC as follows: 
 !" = [!"(!""/100!10!)/0.693147]+ 3 
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Body condition score (BCS) was evaluated on d 0 using a 5-point scale with quarter-
point increments as described by (Edmonson et al., 1989) for Holstein cows.  
Follow up data were retrieved from the study site’s farm management software (DC305, 
Valley Agricultural Software, Tulare, CA). Somatic cell count, milk production, milk 
composition, and clinical mastitis events were recorded for 10 months after enrollment (follow 
up period) or until culling or drying off. 
Analysis of Mineral Concentrations in Serum 
Serum concentrations of calcium, magnesium, phosphorus, copper, iron, potassium, 
manganese, molybdenum, selenium, and zinc were determined by mass spectrometry (Varian 
820-MS, Varian Inc., Palo Alto, CA) at the Veterinary Diagnostic Laboratory (Iowa State 
University, Ames, IA). 
Statistical Analyses 
Sample size calculation was performed using the POWER procedure of SAS version 9.3 
(SAS/STAT, SAS Institute Inc., Cary, NC). A total of 300 cows per treatment was deemed 
necessary to detect a 10 percentage points increase in the proportion of cows cured from 
subclinical mastitis with α = 0.05 and β = 0.20. 
Descriptive statistical analyses were performed using JMP version 11 (SAS Institute Inc., 
Cary, NC) for all following variables at enrollment: BCS, DIM, lactation number, days from 
sampling to treatment, milk yield, milk fat percentage, milk protein percentage, SCC, and LS. 
To evaluate the effect of treatment on the binary outcomes such as subclinical mastitis 
cure and incidences of clinical mastitis and chronic clinical mastitis, logistic regression was 
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performed using the LOGISTIC and GLIMMIX procedures of SAS. The fixed effects of 
treatment, lactation group (1, 2, and ≥ 3 lactations), and the interaction between treatment and 
lactation group were included as independent variables in the statistical models. Results were 
presented as proportions and adjusted odds ratios (AOR) relative to a reference group. 
Continuous outcomes were analyzed by ANOVA fitting a normal distribution. Visual 
assessment of the distribution of studentized residuals and Q-Q plots was performed for each 
dependent variable to ensure normality of residuals and homogeneity of variances. 
Concentrations of minerals in serum on study d 0 and 30 were analyzed in separate models using 
the GLIMMIX procedure of SAS. The models included the fixed effects of treatment, lactation 
group, and the interaction between treatment and lactation group. For analyses of mineral 
concentrations on d 30, data from d 0 were used as covariate. Tukey-adjusted pairwise 
comparisons between lactation groups were performed for mean mineral concentrations at 
enrollment.  
To evaluate the effect of treatment in milk yield, milk fat and protein contents, SCC, and 
linear scores, ANOVA for repeated measures was performed using the MIXED procedure of 
SAS. The fixed effects of treatment, lactation group, time, and the interactions between treatment 
and time, treatment and lactation group, lactation group and time, and treatment, lactation group, 
and time were included as independent variables into the statistical models. To control for 
repeated measurements, cow was considered a random effect. P-values were adjusted using the 
method of Tukey for pairwise comparisons. The first-order autoregressive structure of 
covariance was used in all analyses because it resulted in the lowest Schwarz’s Bayesian 
information criterion value. Results are presented as LSM ± SEM.  
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The effect of injectable trace mineral supplementation on enrollment to removal from the 
herd interval was analyzed by Kaplan-Meier survival analysis using MedCalc version 12.2.1.0 
(MedCalc Software, Ostend, Belgium). Treatment was included in the statistical model as an 
independent variable and P-values were calculated using the Logrank test. For cows that were 
removed from the herd, right censoring was performed based on date of removal, for all other 
animals, censoring was done based on follow up period (date of dry-off). 
For all statistical models, P-value ≤ 0.05 were considered significant and those with 0.05 
< P ≤ 0.10 were considered tendencies.  
RESULTS 
Descriptive Statistics 
Body condition score, DIM, lactation number, milk yield and composition, SCC, and LS 
at enrollment did not differ between treatments (Table 3.2). 
Mineral Concentrations in Serum 
With the exception of calcium and manganese concentrations, which were higher in 
CTRL compared with ITMS cows, mineral concentrations in serum did not differ between 
treatments on d 0 (Table 3.3). Serum concentrations of molybdenum tended to be higher (P = 
0.09) in CTRL compared with ITMS cows on d 30 (Table 3.3). Nevertheless, the remaining 
macro and trace minerals evaluated on d 30 were not affected by treatment. Initial serum 
concentrations of copper, phosphorus and calcium differed between lactation groups (Table 3.3). 
First lactation cows had higher (P ≤ 0.05) circulating concentrations of calcium and phosphorus 
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compared with multiparous cows. In addition, copper and calcium concentrations were lower (P 
≤ 0.05) in cows with three or more lactations. 
Udder Health, Cure of Subclinical Mastitis, and Incidence of Clinical Mastitis 
Injectable trace mineral supplementation did not affect SCC during the follow-up period. 
Somatic cell count was lower (P < 0.01) for first lactation cows, followed by cows in the second 
lactation and those with three or more lactations (551 ± 43, 800 ± 50, and 1,043 ± 55 x 103 
cells/mL, respectively). The interaction between treatment and lactation group did not affect 
SCC. In a similar fashion, treatment and the interaction between treatment and lactation group 
did not affect LS, which were also lower (P < 0.01) for first lactation cows, followed by cows in 
the second lactation and those with three or more lactations (4.0 ± 0.1, 4.6 ± 0.1, and 5.1 ± 0.1, 
respectively). 
The overall proportion of cows cured from subclinical mastitis was 46.3% (287/620), 
whereas the incidences of clinical mastitis and chronic clinical mastitis were 44.4% (275/620) 
and 14.4% (89/620), respectively. Supplementing cows with injectable trace minerals did not 
improve overall cure of subclinical mastitis compared with non-supplemented controls (Table 
3.4). However, a significant effect of parity on cure of subclinical mastitis was observed; cure of 
subclinical mastitis was greater for first lactation cows compared with those in the second 
lactation and three or more lactations (P < 0.01). The analysis within lactation group depicted a 
tendency (P = 0.08) for injectable trace mineral supplementation to increase subclinical mastitis 
cure in cows with three or more lactations. Treatment, lactation group, and their interaction did 
not affect the incidence of clinical mastitis (Table 3.5). Nevertheless, injectable trace mineral 
supplementation tended to reduce (P = 0.09) the overall incidence of chronic clinical mastitis 
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(Table 3.6). Although lactation group had no effect on the proportion of cows diagnosed with 
chronic clinical mastitis, the interaction between treatment and lactation group tended to affect 
(P = 0.06) the incidence of the disease. The proportion of cows diagnosed with chronic clinical 
mastitis during the follow-up period was reduced (P = 0.02) by injectable trace mineral 
supplementation in first lactation cows, but not in cows with two or more lactations. Based on 
survival analyses, treatment had no effect on interval to removal from the herd (Figure 3.1). 
Mineral Concentrations in Serum According to Disease Status 
When animals were compared according to disease status regardless of treatment group, 
cows that recovered from SCM within 30 d of study had higher (P = 0.04) concentrations of 
calcium and tended to have lower (P = 0.10) concentrations of zinc in serum at enrollment 
compared with herdmates that did not recover from the disease (Table 3.7). Cure of SCM was 
associated with higher (P ≤ 0.01) serum concentrations of phosphorus and selenium on d 30. 
Serum concentrations of the remaining minerals did not differ between cows that recovered from 
SCM and herdmates that did not recover from the disease. There was no difference in serum 
mineral concentrations between cows that developed CM and herdmates without clinical signs of 
the disease (Table 3.8). 
Milk Yield and Composition 
Injectable trace mineral supplementation did not improve milk production during the 
follow-up period, which averaged 35.1 ± 0.5 kg for CTRL and 34.5 ± 0.5 kg for ITMS cows. 
Furthermore, milk yield was not affected by lactation group or the interaction between treatment 
and lactation group. Treatment and the interaction between treatment and lactation group had no 
effect on milk fat (CTRL = 3.91 ± 0.03 vs. ITMS = 3.93 ± 0.03%) and protein content (CTRL = 
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3.20 ± 0.02 vs. ITMS = 3.20 ± 0.02%). Milk fat content was greater (P < 0.03) for first as well as 
second lactation cows compared with those with three or more lactations (3.97 ± 0.03, 3.96 ± 
0.03, and 3.82 ± 0.04%, respectively). Milk protein content was also affected by lactation group 
because second lactation (3.25 ± 0.02%) cows had higher (P < 0.02) concentrations compared 
with first lactation cows and those with three or more lactations (3.19 ± 0.02 and 3.15 ± 0.02%, 
respectively). 
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Table 3.1: Total Mixed Ration (TMR) analysis. 
  Dry Matter 
Crude Protein  %  15.6  
Soluble Protein  %  52.0  
Acid Detergent Fiber  %  22.4  
Amylase-Treated Neutral Detergent Fiber  %  36.4  
Lignin  %  2.90  
Non-Fibrous Carbohydrates  %  37.0  
Starch  %  27.6  
Crude Fat  %  4.00  
Ash  %  6.99  
Total Digestible Nutrients  %  72.0  
NEL  Mcal/Kg 1.67  
Calcium  %  0.71  
Phosphorus  %  0.42  
Magnesium  %  0.24  
Potassium  %  1.58  
Sodium  %  0.40  
Iron  mg/kg 234  
Zinc  mg/kg  60.0  
Copper  mg/kg  12.0  
Manganese  mg/kg  40.0  
Molybdenum  mg/kg  1.00  
Selenium  mg/kg  0.49  
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Table 3.2. Descriptive statistics for cows enrolled in the study by treatment group. CTRL = cows 
received no trace mineral supplementation; ITMS = cows received a single injectable trace 
mineral supplementation containing zinc (300 mg), manganese (50 mg), selenium (25 mg), and 
copper (75 mg) at enrollment. Results presented as LSM ± SEM. 
 Treatment  
Variable CTRL (N=314) ITMS (N=306) P 
Enrolled Animals lactation = 1, N 109 131 
0.08 Enrolled Animals lactation = 2, N 120 95 
Enrolled Animals lactation ≥ 3, N 85 80 
Body condition score 3 ± 0.2 3 ± 0.2 0.52 
Days in milk1 144.4 ± 7.1 152.0 ± 7.2 0.45 
Days from sampling to Treatment 7.34 ± 0.1 7.45 ± 0.1 0.57 
Milk yield1, kg 37.8 ± 0.5 37.1 ± 0.5 0.35 
Lactation = 1 33.4 ± 0.8 33.7 ± 0.7 0.77 
Lactation = 2 39.4 ± 0.8 38.9 ± 0.9 0.75 
Lactation ≥ 3 40.7 ± 0.9 40.0 ± 0.9 0.58 
Milk fat1, % 4.08 ± 0.04 4.00 ± 0.04 0.18 
Lactation = 1 4.19 ± 0.07 4.00 ± 0.06 0.05 
Lactation = 2 4.10 ± 0.08 4.08 ± 0.09 0.89 
Lactation ≥ 3 3.93 ± 0.07 3.90 ± 0.07 0.73 
Milk protein1, % 3.17 ± 0.01 3.15 ± 0.02 0.48 
Lactation = 1 3.18 ± 0.03 3.14 ± 0.03 0.40 
Lactation = 2 3.22 ± 0.03 3.22 ± 0.03 0.96 
Lactation ≥ 3 3.11 ± 0.03 3.11 ± 0.03 0.94 
Somatic cell count1, x103 cells/mL  922.0 ± 67.3 885.0 ± 68.2 0.69 
Lactation = 1 852.7 ± 99.4 689.3 ± 90.6 0.22 
Lactation = 2 855.1 ± 110.7 1,096.5 ± 124.5 0.14 
Lactation ≥ 3 1,105.3 ± 146.2 954.0 ± 150.8 0.47 
Linear score1 5.5 ± 0.1 5.4 ± 0.1 0.34 
Lactation = 1 5.5 ± 0.1 5.2 ± 0.1 0.09 
Lactation = 2 5.4 ± 0.1 5.6 ± 0.1 0.31 
Lactation ≥ 3 5.7 ± 0.1 5.5 ± 0.1 0.36 
1 Evaluated at the test day preceding enrollment 
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Table 3.3. Mineral concentrations in serum of cows diagnosed with subclinical mastitis (SCC ≥ 
200 × 103 cells/mL) based on the test day preceding enrollment by treatment group. CTRL = 
cows received no trace mineral supplementation (n = 30); ITMS = cows received a single 
injectable trace mineral supplementation containing zinc (300 mg), manganese (50 mg), 
selenium (25 mg), and copper (75 mg) at enrollment (Lactation = 1: CTRL n=18 and ITMS 
n=12; Lactation = 2: CTRL n=6 and ITMS n=10; Lactation ≥ 3: CTRL n=6 and ITMS n=8). 
Results presented as LSM ± SEM. 
 Enrollment (d 0)  d 30  
Mineral CTRL ITMS P CTRL ITMS P 
Macrominerals       
Calcium, mg/L 94.8 ± 1.1 91.8 ± 1.1 0.07 87.2 ± 0.9 87.2 ± 0.9 0.99 
Lactation = 1 97.4 ± 0.9 97.2 ± 1.1 0.86 87.9 ± 0.9 87.9 ± 1.1 0.95 
Lactation = 2 95.9 ± 1.9 88.6 ± 1.4 0.01 89.0 ± 1.4 84.9 ± 1.1 0.05 
Lactation ≥ 3 85.5 ± 1.9 87.5 ± 1.7 0.46 82.9 ± 2.8 88.9 ± 2.4 0.14 
Magnesium, mg/L 20.0 ± 0.4 19.2 ± 0.4 0.19 19.7 ± 0.4 19.4 ± 0.4 0.66 
Lactation = 1 20.1 ± 0.6 19.6 ± 0.8 0.63 19.4 ± 0.6 18.3 ± 0.8 0.28 
Lactation = 2 20.6 ± 0.6 18.8 ± 0.4 0.04 20.6 ± 0.7 19.5 ± 0.5 0.26 
Lactation ≥ 3 18.8 ± 0.6 18.9 ± 0.5 0.86 19.4 ± 0.6 20.9 ± 0.5 0.12 
Phosphorus, ppm 74.0 ± 2.4 63.4 ± 2.5 0.11 67.3 ± 1.6 64.3 ± 1.6 0.20 
Lactation = 1 79.3 ± 3.1 76.4 ± 3.8 0.55 69.4 ± 2.2 67.9 ± 2.6 0.66 
Lactation = 2 71.9 ± 4.0 66.6 ± 3.1 0.31 64.9 ± 2.7 60.9 ± 2.1 0.27 
Lactation ≥ 3 60.1 ± 3.5 58.4 ± 3.1 0.72 62.9 ± 3.9 62.8 ± 3.4 0.99 
Potassium, mg/L 179.9 ± 2.6 177.1 ± 2.6 0.44 175.5 ± 2.9 176.5 ± 2.9 0.81 
Lactation = 1 180.7 ± 3.2 179.5 ± 4.0 0.81 172.4 ± 3.3 169.1 ± 4.0 0.53 
Lactation = 2 185.7 ± 6.9 176.2 ± 5.3 0.29 178.8 ± 6.4 179.7 ± 5.0 0.91 
Lactation ≥ 3 172.0 ± 5.3 174.5 ± 4.6 0.72 181.5 ± 7.7 183.4 ± 6.6 0.85 
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Table 3.3. (continued) 
 Enrollment (d 0)  d 30  
Mineral CTRL ITMS P CTRL ITMS P 
Trace minerals       
Copper, mg/L 0.92 ± 0.03 0.85 ± 0.03 0.12 0.82 ± 0.03 0.77 ± 0.03 0.25 
Lactation = 1 0.99 ± 0.03 0.91 ± 0.04 0.17 0.85 ± 0.02 0.76 ± 0.03 0.06 
Lactation = 2 0.93 ± 0.04 0.84 ± 0.03 0.13 0.88 ± 0.07 0.81 ± 0.05 0.46 
Lactation ≥ 3 0.66 ± 0.04 0.76 ± 0.03 0.11 0.65 ± 0.05 0.73 ± 0.05 0.28 
Iron, mg/L 2.5 ± 0.2 2.3 ± 0.2 0.40 2.3 ± 0.2 2.4 ± 0.2 0.71 
Lactation = 1 2.38 ± 0.26 2.36 ± 0.32 0.95 2.3 ± 0.2 2.26 ± 0.25 0.92 
Lactation = 2 2.86 ± 0.48 2.66 ± 0.37 0.74 2.48 ± 0.35 2.28 ± 0.27 0.65 
Lactation ≥ 3 2.70 ± 0.5 1.72 ± 0.43 0.16 2.08 ± 0.56 2.71 ± 0.49 0.41 
Manganese, ug/L 4.3 ± 0.2 3.5 ± 0.2 0.05 3.3 ± 0.8 4.8 ± 0.8 0.23 
Lactation = 1 4.27 ± 0.38 3.41 ± 0.47 0.16 2.83 ± 0.35 3.66 ± 0.43 0.14 
Lactation = 2 4.33 ± 0.54 4.0 ± 0.42 0.63 2.66 ± 0.26 3.5 ± 0.2 0.02 
Lactation ≥ 3 4.16 ± 0.43 3.12 ± 0.37 0.09 5.33 ± 3.85 8 ± 3.33 0.61 
Molybdenum, ug/L 8.70 ± 0.40 8.10 ± 0.40 0.26 9.7 ± 0.4 8.7 ± 0.4 0.09 
Lactation = 1 8.38 ± 0.53 7.83 ± 0.65 0.51 9.22 ± 0.56 8.50 ± 0.68 0.42 
Lactation = 2 8.66 ± 0.99 8.50 ± 0.77 0.89 10.5 ± 1.0 8.1 ± 0.8 0.08 
Lactation ≥ 3 9.83 ± 0.65 8.00 ± 0.56 0.05 10.5 ± 0.9 9.62 ± 0.86 0.51 
Selenium, ug/L 132 ± 3. 129 ± 3 0.51 126 ± 3 127 ± 3 0.94 
Lactation = 1 130 ± 3 130 ± 4 0.94 125 ± 3 124 ± 4 0.84 
Lactation = 2 131 ± 5 127 ± 4 0.51 133 ± 8 121 ± 6 0.23 
Lactation ≥ 3 138 ± 7 132 ± 6 0.57 123 ± 7 138 ± 6 0.16 
Zinc, mg/L 0.83 ± 0.03 0.83 ± 0.03 1.00 0.87 ± 0.03 0.89 ± 0.03 0.65 
Lactation = 1 0.85 ± 0.03 0.87 ± 0.04 0.75 0.85 ± 0.04 0.91 ± 0.05 0.31 
Lactation = 2 0.81 ± 0.07 0.87 ± 0.05 0.57 0.93 ± 0.06 0.91 ± 0.05 0.78 
Lactation ≥ 3 0.78 ± 0.04 0.72 ± 0.03 0.30 0.86 ± 0.06 0.82 ± 0.06 0.65 
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Table 3.4. Logistic regression model for the effect of injectable trace mineral supplementation 
on subclinical mastitis cure (SCC < 200 × 103 cells/mL) of cows diagnosed with subclinical 
mastitis (SCC ≥ 200 × 103 cells/mL) on the test day preceding enrollment. CTRL = cows 
received no trace mineral supplementation (n = 314); ITMS = cows received a single injectable 
trace mineral supplementation containing zinc (300 mg), manganese (50 mg), selenium (25 mg), 
and copper (75 mg) at enrollment (n = 306). 
 
Variable Level Cured1, % (n) OR2  P 
Treatment 
CTRL 42.8 (314) Reference 
0.38 
ITMS 46.5 (306) 1.16 
Parity 
Lactation = 1 58.5 (240) Reference 
< 0.001 Lactation = 2 42.8 (215) 0.53 
Lactation ≥ 3 33.2 (165) 0.35 
Parity * Treatment 
Lactation = 1 - CTRL 60.6 (109) Reference 
0.53 
Lactation = 1 - ITMS 56.5 (131) 0.85 
Lactation = 2 - CTRL 42.5 (120) Reference 
0.92 
Lactation = 2 - ITMS 43.2 (95) 1.03 
Lactation ≥ 3 - CTRL 27.1 (85) Reference 
0.08 
Lactation ≥ 3 - ITMS 40.0 (80) 1.80 
1 Data presented as proportions adjusted by the logistic regression model. 
2 Odds ratios (OR) from the logistic regression model. 
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Table 3.5. Logistic regression model for the effect of injectable trace mineral supplementation 
on the incidence of clinical mastitis in cows diagnosed with subclinical mastitis (SCC ≥ 200 × 
103 cells/mL) on the test day preceding enrollment. CTRL = cows received no trace mineral 
supplementation (n = 314); ITMS = cows received a single injectable trace mineral 
supplementation containing zinc (300 mg), manganese (50 mg), selenium (25 mg), and copper 
(75 mg) at enrollment (n = 306). 
 
Variable Level CM1, % (n) OR2  P 
Treatment 
CTRL 48.2 (314) Reference 
0.11 
ITMS 41.7 (306) 0.77 
Parity 
Lactation = 1 42.0 (240) Reference 
0.30 Lactation = 2 43.3 (215) 1.05 
Lactation ≥ 3 49.5 (165) 1.36 
Parity * Treatment 
Lactation = 1 - CTRL 45.9 (109) Reference 
0.23 
Lactation = 1 - ITMS 38.2 (131) 0.73 
Lactation = 2 - CTRL 43.3 (120) Reference 
0.98 
Lactation =2 - ITMS 43.2 (95) 0.99 
Lactation ≥ 3 - CTRL 55.3 (85) Reference 
0.14 
Lactation ≥ 3 - ITMS 43.8 (80) 0.63 
1 Clinical mastitis (CM) was defined as abnormal milk with clots in a forestripping test. Adjusted 
proportions according to the logistic regression model. 
2 Odds ratios (OR) from the logistic regression model. 
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Table 3.6. Logistic regression model for the effect of injectable trace mineral supplementation 
on the incidence of chronic clinical mastitis in cows diagnosed with subclinical mastitis (SCC ≥ 
200 × 103 cells/mL) on the test day preceding enrollment. CTRL = cows received no trace 
mineral supplementation (n = 314); ITMS = cows received a single injectable trace mineral 
supplementation containing zinc (300 mg), manganese (50 mg), selenium (25 mg), and copper 
(75 mg) at enrollment (n = 306). 
 
Variable Level CCM1, % (n) OR2  P 
Treatment 
CTRL 16.9 (314) Reference 
0.09 
ITMS 12.0 (306) 0.67 
Parity 
Lactation = 1 12.0 (240) Reference 
0.13 Lactation = 2 12.7 (215) 1.06 
Lactation ≥ 3 18.9 (165) 1.71 
Parity * Treatment 
Lactation = 1 - CTRL 18.4 (109) Reference 
0.02 
Lactation = 1 - ITMS 7.6 (131) 0.37 
Lactation = 2 - CTRL 10.8 (120) Reference 
0.39 
Lactation = 2 - ITMS 14.7 (95) 1.42 
Lactation ≥ 3 - CTRL 23.5 (85) Reference 
0.17 
Lactation ≥ 3 - ITMS 15.0 (80) 0.57 
1 Chronic clinical mastitis (CCM) was defined as three or more cases of clinical mastitis. All 
cows included in the study were diagnosed with subclinical mastitis (SCC ≥ 200 × 103 cells/mL) 
on the test day preceding enrollment. Adjusted proportions from the logistic regression model. 
2 Odds ratios (OR) from the logistic regression model. 
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Table 3.7. Mineral concentrations in serum according to cure of subclinical mastitis (SCM). 
Cured = SCC < 200 × 103 cells/mL (n = 27). SCM= SCC ≥ 200 × 103 cells/mL (n = 33). All 
cows were diagnosed with subclinical mastitis (SCC ≥ 200 × 103 cells/mL) on the test day 
preceding enrollment. Results presented as LSM ± SEM. 
 
 Enrollment (d 0)  d 30  
Mineral SCM Cured P SCM Cured P 
Macrominerals       
Calcium, mg/L 91.8 ± 1.1 95.1 ± 1.2 0.04 86.8 ± 0.9 87.7 ± 1.0 0.45 
Magnesium, mg/L 19.6 ± 0.4 19.6 ± 0.4 0.93 19.7 ± 0.4 19.4 ± 0.5 0.71 
Phosphorus, mg/L 69.5 ± 2.4 73.3 ± 2.6 0.30 62.3 ± 1.4 69.9 ± 1.6 < 0.01 
Potassium, mg/L 176.0 ± 2.5 181.6 ± 2.8 0.14 176.6 ± 2.8 175.3 ± 3.1 0.74 
Trace minerals       
Copper, mg/L 0.87 ± 0.03 0.90 ± 0.03 0.39 0.80 ± 0.03 0.79 ± 0.03 0.73 
Iron, mg/L 2.3 ± 0.2 2.5 ± 0.2 0.57 2.3 ± 0.2 2.4 ± 0.20 0.65 
Manganese, ug/L 3.8 ± 0.3 4.0 ± 0.3 0.63 4.7 ± 0.8 3.3 ± 0.9 0.25 
Molybdenum, ug/L 8.8 ± 0.4 8.0 ± 0.4 0.14 9.3 ± 0.4 9.1 ± 0.5 0.72 
Selenium, ug/L 130 ± 3 133 ± 3 0.30 122 ± 3 132 ± 3 0.01 
Zinc, mg/L 0.86 ± 0.03 0.80 ± 0.03 0.10 0.88 ± 0.03 0.88 ± 0.03 0.95 
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Table 3.8. Mineral concentrations in serum according to occurrence of clinical mastitis (CM) in 
cows diagnosed with subclinical mastitis (SCC ≥ 200 × 103 cells/mL) on the test day preceding 
enrollment. CM = animals with abnormal milk during a forestripping test (n = 26) Normal = 
cows that had normal milk at every test during the follow-up period (n = 34). Results presented 
as LSM ± SEM. 
 
 Enrollment (d 0)  d 30  
Mineral Normal CM P Normal CM P 
Macrominerals       
Calcium, mg/L 93.0 ± 1.1 93.7 ± 1.3 0.69 87.1 ± 0.9 87.4 ± 1.0 0.83 
Magnesium, mg/L 19.4 ± 0.4 19.8 ± 0.5 0.54 19.5 ± 0.4 19.6 ± 0.5 0.85 
Phosphorus, mg/L 69.5 ± 2.3 73.4 ± 2.7 0.28 65.5 ± 1.6 66.1 ± 1.8 0.79 
Potassium, mg/L 178.3 ± 2.5 178.9 ± 2.9 0.86 175.3 ± 2.8 176.9 ± 3.1 0.70 
Trace minerals       
Copper, mg/L 0.87 ± 0.02 0.90 ± 0.03 0.40 0.78 ± 0.03 0.82 ± 0.03 0.34 
Iron, mg/L 2.4 ± 0.2 2.5 ± 0.2 0.81 2.5 ± 0.2 2.2 ± 0.2 0.20 
Manganese, ug/L 4.1 ± 0.3 3.7 ± 0.3 0.34 3.4 ± 0.8 4.9 ± 0.9 0.22 
Molybdenum, ug/L 8.0 ± 2.4 8.9 ± 0.4 0.12 9.2 ± 0.4 9.2 ± 0.5 0.90 
Selenium, ug/L 128 ± 2 134 ± 3 0.11 126 ± 3 127 ± 3 0.99 
Zinc, mg/L 0.84 ± 0.03 0.83 ± 0.03 0.79 0.91 ± 0.03 0.85 ± 0.03 0.17 
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Figure 3.1. Kaplan-Meier survival analysis of time from enrollment to removal from the herd. 
CTRL = cows with subclinical mastitis that received no mineral supplementation (n = 314; solid 
line); ITMS = cows with subclinical mastitis treated with an injectable trace mineral supplement 
(zinc, 300 mg; manganese, 50 mg; selenium, 25 mg; copper,75 mg) on d 0 (n = 306; dashed 
line). The mean enrollment to removal from the herd interval were 239.6 and 239.3 d for CTRL 
and ITMS, respectively (P = 0.94). 
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DISCUSSION 
Although injectable trace mineral supplementation containing selenium, copper, zinc, and 
manganese during the prepartum period has been shown to reduce SCC throughout the first five 
months of lactation (Machado et al., 2013), its effects on health and productive performance of 
lactating dairy cows diagnosed with subclinical mastitis remains elusive. The requirements for 
trace minerals in lactating dairy cow diets have been calculated based on studies that focused in 
reproductive performance, milk production, and stability of skeletal system, rather than targeting 
optimum immune function. To the best of our knowledge, only copper and selenium had aspects 
of the immune function taken into consideration during requirement calculation. Therefore, it is 
possible that the trace minerals needed for optimum udder health have been underestimated. It is 
important to highlight that in the present study, mineral status of the study population was 
assessed through blood mineral panel analysis in a subset of animals at enrollment and all blood 
concentrations of minerals evaluated were in accordance with previously reported normal values 
(Dargatz and Ross, 1996, Kincaid, 2000, NRC, 2001). Mineral supplementation in lactating dairy 
cows with normal levels of blood minerals and with SCC ≥ 200 × 103 cells/mL significantly 
reduced the incidence of chronic clinical mastitis in primiparous cows, tended to reduce overall 
incidence of chronic clinical mastitis, and tended to improve subclinical mastitis cure in cows 
with three or more lactations. Nevertheless, ITMS did not significantly affect survival, milk 
yield, or milk composition in cows diagnosed with subclinical mastitis 
Genther and Hansen (2014) supplemented beef steers with the same mineral combination 
used in the present study and reported increases in circulating concentrations of manganese and 
selenium for 1 and 15 days following injection, respectively. Similar to our results, that group 
did not observe differences in serum mineral concentrations between treatment and control 
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groups on d 29 post-injection; however, liver copper and selenium contents were higher in 
supplemented steers. One explanation for the similar blood mineral concentrations between 
ITMS and CTRL groups in the current trial could be the timing of sample collection. 
Supplemental minerals in ITMS could have been cleared through homeostatic processes or have 
been stored in body reserves. Given the circumstances of the present study, it was not possible to 
perform liver biopsies on d 30 to assess the effect of ITMS on other body reserves.  
 Our results indicate that the administration of ITMS can be used as a strategy to lower 
the incidence of chronic clinical mastitis in primiparous cows diagnosed with elevated SCC. The 
importance of trace minerals in the immune system and mammary health has been reported in 
several studies (Andrieu, 2008, O'Rourke, 2009, Overton and Yasui, 2014). Elevated SCC has 
been associated with greater odds of developing clinical mastitis (Peeler et al., 2003). Previous 
work from our group reported significantly lower odds of developing clinical mastitis in 
multiparous animals that received injectable trace mineral supplementation containing selenium, 
copper, zinc, and manganese during the dry period (Machado et al., 2013). The differences found 
between the results presented here and data reported by Machado et al. (2013) might be due to 
dissimilarities in the target population and the frequency of supplementation between studies. 
We supplemented lactating animals experiencing subclinical mastitis with a single dose of ITMS 
while the former work aimed to evaluate the effect of a three doses supplementation of healthy 
cows during the transition period. In that study, injectable trace mineral supplementation 
containing selenium, copper, zinc, and manganese was given at approximately 230 and 260 days 
of gestation and again at 35 DIM. 
In the present study, injectable trace mineral supplementation of selenium, copper, zinc, 
and manganese also tended to increase subclinical mastitis cure in cows of third or greater 
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lactation. We observed that this group of animals had the lowest initial serum concentrations of 
copper, calcium and phosphorus. Cows of third or greater lactation were also the highest milk 
producing group; therefore, mineral requirements for those animals could possibly have been 
underestimated, and might explain why the supplementation with ITMS had an effect of 
subclinical mastitis cure in this group.  
When animals were compared across treatments based on disease status, serum 
concentration of selenium on d 30 was lower in animals that remained affected with subclinical 
mastitis. Selenium is an essential element of the antioxidant enzymes glutathione peroxidase and 
thioredoxin reductase, playing a role in regulation and host cell resistance to reactive oxygen 
species (ROS) (McKenzie et al., 2002). Nonetheless, all animals in the present study had 
adequate selenium levels in both time points. In dairy cows, selenium supplementation has been 
associated with better neutrophil function (Ibeagha et al., 2009), decreased prevalence of 
mammary infections (Erskine et al., 1987, Jukola et al., 1996), and improved antioxidant status 
and immune function (Hall et al., 2014). Studies that used supplementation of bovine mammary 
cells in vitro suggested that selenium supplementation plays a role in the optimization of udder 
health in via increased resistance to oxidative stress (Miranda et al., 2011). 
In addition to differences in selenium status between cows that underwent subclinical 
mastitis cure and those that remained with SCC above 200 × 103 cells/mL, associations between 
macro mineral concentrations and mammary gland health were observed. We identified that 
cows that experienced subclinical mastitis cure had higher concentrations of serum calcium on d 
0. Circulating calcium levels have been associated with bovine immune function and disease 
status in other studies (Curtis et al., 1983, Kimura et al., 2006, Martinez et al., 2012). A study 
conducted in Florida reported that neutrophils isolated from cows with lower serum calcium in 
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the transition period had impaired in vitro phagocytosis and bacterial killing capacity, fewer 
circulating leucocytes, a more pronounced decrease in neutrophil count postpartum, and 
increased incidence of metritis (Martinez et al., 2012). That group evaluated the effects of 
subclinical hypocalcemia in dairy cows; however it is important to highlight that the study 
population herein had levels of calcium above of the cutoff of 8.59 mg/dl in which a cow is 
considered subclinically hypocalcemic. Nevertheless, circulating calcium levels have been 
directly correlated with amounts of releasable calcium in the endoplasmic reticulum (Kimura et 
al., 2006), playing a role in bovine neutrophil activation, ROS production, and degranulation, all 
of which are critical for proper immune function (Tintinger et al., 2005, Burgos et al., 2011). 
In the present study, higher phosphorus concentrations were associated with subclinical 
mastitis cure. Cows that recovered from the disease by d 30 had higher serum concentrations of 
phosphorus on d 30 compared with those that remained with SCC ≥ 200 × 103 cells/mL. Limited 
research associating phosphorus and bovine immune function is available. Mullarky et al. (2009) 
found that supplementing lactating dairy cows with no (0.34%, no supplementary P), medium 
(0.43%), or high (0.52%) levels of phosphorus did not influence lymphocyte proliferation and 
neutrophil killing ability in vitro. Further research is necessary to evaluate the effect of 
phosphorus supplementation beyond required levels in dairy cows’ immune function. 
Although copper and zinc levels were not different between treatment groups nor 
associated with SCM cure or decreased odds of chronic CM; it is well known that these minerals 
are components of the enzyme superoxide dismutase (SOD), which has been previously 
associated with udder health (Machado et al., 2014). Additionally, Blanco-Penedo et al. (2014) 
reported that herds with low manganese had increased odds of CM as compared to herds with 
adequate levels of manganese, and that low copper levels were associated with increased odds of 
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CM cases for second lactation cows. Nevertheless, one cannot exclude the possibility of multiple 
factors, other than a specific mineral level, play a role in associations observed in survey-type 
studies such as the one conducted by Blanco-Penedo and colleagues in 2014. Further research is 
necessary to evaluate repeated ITMS supplementation to lactating dairy cows with elevated 
somatic cell counts belonging to various parity groups. Perhaps the administration of sequential 
doses of ITMS to animals with subclinical mastitis would be effective in providing supplemental 
trace minerals for improved udder health. 
CONCLUSIONS 
A single subcutaneous injection containing zinc, manganese, selenium, and copper 
administered to dairy cows with elevated SCC reduced the incidence of chronic clinical mastitis, 
particularly in primiparous cows, and tended to increase subclinical mastitis cure in cows with 
three or more lactations. Supplementation had no effect on milk production and composition in 
cows with elevated SCC. Regardless of supplementation, cows that were cured of subclinical 
mastitis had lower serum concentrations of zinc at diagnosis and higher selenium and 
phosphorus concentrations 30 d later compared with herdmates that maintained SCC above 200 
× 103 cells/mL; thereby, supporting a possible role for availability and utilization of trace 
minerals for maintenance of udder health. 
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ABSTRACT 
Antimicrobial usage in food animals has a direct impact on human health, and 
approximately 80% of the antibiotics prescribed in the dairy industry are used to treat bovine 
mastitis. Here, we provide a longitudinal description of the changes in the microbiome of milk 
that are associated with mastitis and antimicrobial therapy. Next-generation sequencing, 16S 
rRNA gene quantitative real-time PCR, and aerobic culturing were applied to assess the effect of 
disease and antibiotic therapy on the milk microbiome. Cows diagnosed with clinical mastitis 
associated with Gram-negative pathogens or negative aerobic culture were randomly allocated 
into 5 days of Ceftiofur intramammary treatment or remained as untreated controls. Serial milk 
samples were collected from the affected quarter and the ipsilateral healthy quarter of the same 
animal. Milk from the mastitic quarter had a higher bacterial load and reduced microbial 
diversity compared to healthy milk. Resolution of the disease was accompanied by increases in 
diversity indexes and a decrease in pathogen relative abundance. Escherichia coli-associated 
mastitic milk samples had a remarkably distinct bacterial profile, dominated by 
Enterobacteriaceae, when compared to healthy milk. However, no differences were observed in 
culture-negative mastitis samples when compared to healthy milk. Antimicrobial treatment had 
no significant effect on clinical cure, bacteriological cure, pathogen clearance rate or bacterial 
load. 
INTRODUCTION 
Production of animal protein to support the world’s growing human population is one of 
the main challenges facing humankind. Concerns related to food safety and development of 
antimicrobial resistance may lead to decreased availability of antibiotics for use in food animals 
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and thereby limit our ability to control disease in agricultural animal species. Such a change in 
antibiotic usage in food animals could also alter perspectives on food security as it relates to 
public health concerns regarding antibiotic use in food animals. Thus, in-depth understanding of 
disease mechanisms is critical to promote animal health and at the same time encourage 
judicious use of antibiotics in livestock. Mastitis is one of the most common diseases in dairy 
herds, and approximately 20% to 30% of dairy cows develop clinical mastitis at least once 
during lactation (Sargeant et al., 1998, Hertl et al., 2014). Not surprisingly, prophylaxis and 
treatment of mastitic cows are the major reasons for antibiotic usage in dairy farms (Erskine et 
al., 2003, Pol and Ruegg, 2007).  
Maternal milk harbors a rich microbial community that is vital for establishment of the 
gut microbiome and immune tolerance in neonates (Martin et al., 2003, Bertelsen et al., 2014). 
The same microbial community in the mammary gland may provide an environment that aids the 
host in preventing mammary infections. For instance, commensal bacteria present in human milk 
inhibit proliferation of Staphylococcus aureus (Heikkila and Saris, 2003), which is also a 
pathogen commonly associated with mastitis in dairy cows (Olde Riekerink et al., 2008). 
Considering that mastitis possibly reflects a dysbiosis within the mammary gland (Oikonomou et 
al., 2012, Kuehn et al., 2013, Oikonomou et al., 2014), a detailed assessment of the milk 
microbiome during active stages of clinical disease, spontaneous recovery, treatment and post-
treatment is essential to further elucidate this pathological condition. 
The multifactorial etiology of mastitis presents a major challenge for disease prevention 
and treatment of affected animals. Implementation of programs for mastitis control has reduced 
the prevalence of important contagious pathogens, and approximately 40% of clinical cases of 
mastitis are associated with opportunistic Gram-negative bacteria such as Escherichia coli, 
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Klebsiella spp., Pseudomonas spp., and Pasteurella spp. (Erskine et al., 1988, Olde Riekerink et 
al., 2008, Botrel et al., 2010). Although current guidelines do not recommend the use of 
intramammary antibiotics for cows diagnosed with Gram-negative mastitis (Erskine et al., 2003, 
Suojala et al., 2013), improved bacteriological and clinical outcomes have been shown in 
mastitic cows treated with third-generation cephalosporins compared with other antimicrobials or 
untreated controls (Schukken et al., 2011a, Schukken et al., 2013). However, the impact of these 
broad-spectrum antibiotics on the milk microbiota (other than major pathogens) remains 
unknown. In fact, currently no data concerning the effect of antibiotic therapy on the mammary 
microbiota are available in either humans or animals. Routine methods used to assess responses 
to intramammary treatments overlook numerous microorganisms, which is supported by the fact 
that 40% of milk samples collected from cows with clinical mastitis yield negative results by 
aerobic culture (Botrel et al., 2010). Later-generation cephalosporins have broad-spectrum 
antibacterial activity, so their use could unintentionally disrupt general mammary microbial 
populations and also increase the risk of antimicrobial resistance if not used in a judicious 
manner (Dolejska et al., 2012). Understanding the dynamics of the mammary microbiota upon 
antibiotic therapy is essential not only for development of effective treatment strategies, but also 
to facilitate the process of restoring a healthy mammary microbiota. 
State-of-the-art technologies have allowed the investigation of microbial communities in 
milk without some of the limitations imposed by culture methods (Hunt et al., 2011, Cabrera-
Rubio et al., 2012, Oikonomou et al., 2012). Therefore, the specific objectives of the present 
study were: 1) to use high-throughput DNA sequencing to describe the microbiome of milk in 
dairy cows affected by clinical mastitis associated with Gram-negative bacteria or negative 
culture; 2) to determine the bacterial load based on PCR quantification of 16S rRNA gene 
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copies, and compare microbial populations of affected and healthy quarters; and 3) to assess the 
effect of intramammary treatment with ceftiofur hydrochloride on the milk microbiome, bacterial 
load, and clinical cure in quarters affected with clinical mastitis.  
MATERIALS AND METHODS 
Ethics Statement 
The research protocol was reviewed and approved by the Cornell University Institutional 
Animal Care and Use Committee (protocol number 2013-0056). The methods were carried out in 
accordance with the approved guidelines. 
Animals, Enrollment Criteria, and Treatments 
Milk samples were collected from lactating Holstein cows diagnosed with clinical 
mastitis between April and June, 2014. All cows were housed in a single herd located in upstate 
New York which milked approximately 2,800 cows thrice daily during the experimental period. 
Clinical mastitis was defined as the presence of at least visually abnormal milk (i.e. presence of 
flakes, clots, or serous milk) during forestripping performed at the milking parlor. Once mastitis 
was diagnosed, the initial milk sample for mastitis pathogen identification was collected by 
trained farm personnel according to National Mastitis Council guidelines (NMC, 1999). These 
samples were defined as day 0 samples. Teats were cleaned and disinfected using 70% ethanol 
(v/v), the initial three streams were discarded, and approximately 5 mL of milk was collected 
into a sterile plastic tube without preservative (Corning Life Sciences, Tewksbury, MA). Milk 
samples were cultured using an on-farm chromogenic culture system for fast identification of 
causal agents (Accumast®, FERA Animal Health LCC, Ithaca, NY) according to the 
manufacturer’s recommendations, and then submitted for analysis at the Quality Milk Production 
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Services laboratory (QMPS; Cornell University, Ithaca, NY) to ensure the accuracy of on-farm 
culture. Disagreement between methods was observed in only two samples, which were excluded 
from further analyses after the results from QMPS were received. 
Cows diagnosed with clinical mastitis associated with Gram-negative bacteria or negative 
on-farm culture and that had not been treated with intramammary antimicrobials in the 14 days 
preceding diagnosis were deemed eligible for enrollment. On study day 1, eligible cows were 
randomly allocated into one of two treatments based on a list of numbers generated using the 
RAND function of Excel (Microsoft, Redmond, WA), blocked by aerobic culture results. 
Clinical score was assessed on days 1, 8, 10 and 14 according to Wenz et al (Wenz et al., 2001, 
Wenz et al., 2006). Milk appearance, mammary gland appearance and systemic signs of disease 
(i.e. rectal temperature ≥ 39.5 ºC, dehydration and depression) were evaluated for classification 
of clinical score. A clinical score of ‘mild’ was assigned if only abnormal milk was observed. A 
‘moderate’ score was assigned when abnormal milk and inflammation of the mammary gland 
were present. A ‘severe’ score was assigned if abnormal milk, local inflammation and one or 
more of the systemic signs of the disease were observed. 
Cows assigned to the treatment group received daily intramammary infusions containing 
125 mg of ceftiofur equivalents (as ceftiofur hydrochloride; Spectramast LC®, Zoetis, Florham 
Park, NJ) only on the mastitic quarter for five consecutive days, whereas those assigned to the 
control group did not receive intramammary therapy. 
Sample and Data Collection 
Serial milk samples were collected by a trained veterinarian member of the research team 
from each cow on study days 1, 2, 3, 4, 5, 8, 10, and 14, from both the mastitic quarter and the 
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ipsilateral healthy quarter of the same cow. For cows in the treated group, sampling on days 1 
through 5 was performed after milk out of the quarter in untreated cows, whereas treated cows 
were sampled immediately before intramammary treatments were applied. Teats were 
disinfected as described above and 10 mL of milk was harvested from each quarter into a sterile 
plastic tube without preservative (Corning Life Sciences, Tewksbury, MA). Samples were 
immediately refrigerated at 4 ºC, transported to the laboratory on ice, and frozen at -20 ºC until 
assayed. Milk samples collected from mastitic quarters on days 10 and 14 were submitted to the 
QMPS laboratory for bacterial identification using standard aerobic culture. 
Clinical cure was defined as cows without any clinical signs on both day 10 and day 14. 
Bacteriological cure was defined as both the samples taken on day 10 and day 14 being negative 
for the organism present on day 0. In all other cases the quarter was considered to be a non-cure 
or treatment failure. Bacteriological cure can only be evaluated in quarters that were culture 
positive on day 0. 
DNA Isolation and Purification 
Milk samples were thawed, homogenized by inverting the tubes, and a 6-mL aliquot was 
taken for DNA isolation and purification. Milk samples were centrifuged at 4 ºC and 16,100 × g 
for 3 minutes and the supernatant was discarded. Genomic DNA was isolated from the remaining 
pellet using a commercially available kit (PowerFood DNA Isolation Kit, MO BIO Laboratories 
Inc., Carlsbad, CA) as described previously (Quigley et al., 2012). Concentration and purity of 
isolated DNA were evaluated based on optical density at 230, 260 and 280 nm wavelengths 
(NanoDrop ND-1000, NanoDrop Technologies, Wilmington, DE). 
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Amplification of the V4 Hypervariable Region of the Bacterial 16S rRNA Gene, 
Library Preparation, and 16S rRNA Gene Sequencing 
The V4 hypervariable region of the bacterial 16S rRNA gene was amplified from 
genomic DNA by PCR utilizing the primers 515F and 806R optimized for the Illumina MiSeq 
platform (Illumina Inc., San Diego, CA) (Caporaso et al., 2012) as described previously 
(Foditsch et al., 2015). 
 Equimolar libraries were sequenced in six runs using the MiSeq reagent kit V2 for 300 
cycles on the MiSeq platform (Illumina). Each run included 279 samples and a sequencing 
control that consisted of the purified barcoded PCR product of DNA extracted from 
Staphylococcus aureus (ATCC 25923). Gene sequences were processed using the 16S 
Metagenomics workflow in the MiSeq Reporter analysis software version 2.5 based on quality 
scores generated by real-time analysis during the sequencing run. Quality-filtered indexed reads 
were demultiplexed for generation of individual FASTQ files and aligned using the banded 
Smith-Waterman method of the Illumina-curated version of the Greengenes database for 
taxonomic classification of milk microbes. Resulting FASTQ files were uploaded into the open-
source pipeline Quantitative Insights into Microbial Ecology (QIIME) version 1.9.1 (Caporaso 
et al., 2010b). Sequences were filtered based on quality as described previously (Bokulich et al., 
2013) and assigned to operational taxonomic units (OTUs) with 97% identity using UCLUST 
(Edgar, 2010). The OTU database was rarefied using the command single_rarefaction.py from 
QIIME and the number of OTUs, as well as Chao1 and Shannon indexes, was calculated for each 
sample at a rarefication level of 5,000 reads per sample. 
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Quantification of 16S rRNA Copies by qPCR 
The number of 16S rRNA copies was used as a proxy to determine bacterial load in milk 
samples collected on days 1, 3, 8 and 14. 16S rRNA gene copies were quantified by qPCR as 
described previously (Boutin et al., 2015). Reactions were performed using Unibac primers 
(forward: 5′-TGG AGC ATG TGG TTT AAT TCG A-3′; reverse: 5′-TGC GGG ACT TAA CCC 
AAC A-3′; 50 pmol/reaction), 1X iQTM SYBR® Green Mastermix (Bio-Rad Laboratories, 
Hercules, CA), and 1.5 µL of sample DNA. A standard curve was built using plasmid DNA 
quantified by spectrophotometry. All samples were assayed in duplicate using an iQTM5 Real-
time PCR system (Bio-Rad Laboratories, Hercules, CA) set to perform denaturation at 95 ºC for 
3 minutes, then 40 cycles of amplification (95 ºC for 10 seconds and 55 ºC for 30 seconds), one 
cycle at 95 ºC for 60 seconds, one cycle at 55 ºC for 60 seconds, and a melting curve 
determination.  
Statistical Analyses 
Descriptive analyses on sequencing results were performed using the UNIVARIATE 
procedure of SAS version 9.3 (SAS Institute Inc., Cary, NC). Differences in the relative 
abundance of bacteria between quarters with clinical mastitis and healthy counterparts were 
evaluated at the phylum and family levels using JMP Pro 11 (SAS Institute Inc., Cary, NC). 
Cows were categorized according to the main pathogen identified on samples taken on study day 
0 through standard culture methods into four groups, namely E. coli, Klebsiella spp., 
Pseudomonas spp., and negative culture. Within each group, the effect of clinical mastitis on the 
relative abundance of each of the ten most prevalent phyla was evaluated by ANOVA. The 
prevalences of all remaining phyla were combined into a single cluster. The fixed effect of 
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disease (healthy vs. mastitic quarters) was included in the statistical models as an independent 
variable. Response screening was performed to assess the effect of clinical mastitis on the 
relative abundance of the 100 most prevalent families in each pathogen group. P-values were 
adjusted for false discovery rate (FDR) (Benjamini and Hochberg, 1995), and presented as FDR 
LogWorth (i.e. -log10P). The mean relative abundance for each family observed across all 
healthy quarters was used as a reference for calculation of fold-changes. 
Microbiome changes occurring over time and in response to intramammary antibiotic 
therapy were described for the 25 most prevalent families in each pathogen group using the 
tabulate function of JMP Pro 11. Relative abundances of all remaining families were combined 
into a single cluster. The magnitude of change was scaled uniformly within health status (healthy 
vs. mastitic quarters). The relative abundances of major pathogens associated with clinical 
mastitis were evaluated within pathogen groups by ANOVA for repeated measures using the 
GLIMMIX procedure of SAS. Outcomes were the relative abundance of each pathogen and the 
explanatory variables were treatment, time, health status (healthy vs mastitic quarter) and their 
two- and three-way interactions. Cow was considered a random effect in all statistical models. 
Time changes in the number of OTUs, Chao1 index, and Shannon index were analyzed by 
ANOVA for repeated measures using the GLIMMIX procedure of SAS. Within each pathogen 
group, two statistical models were built to evaluate the effects of mastitis (i.e. fixed effects of 
mastitis, time, and interaction between mastitis and time) and treatment (i.e. fixed effects of 
treatment, mastitis, time, and all two- and three-way interactions).  
The effect of cure on the relative abundance of Enterobacteriaceae family members and 
the Shannon diversity index was evaluated between cured and non-cured cows with clinical 
mastitis associated with E. coli by ANOVA for repeated measures using the Fit Model function 
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on JMP Pro 11. Tests for normality of residuals and homogeneity of variances were conducted 
for each dependent variable, and data that did not fulfill ANOVA assumptions were transformed 
accordingly (i.e. 16S rRNA gene copy numbers). The covariance structure with the smallest 
Schwarz’s Bayesian information criterion value was selected for each analysis. Differences with 
P ≤ 0.05 were considered significant and those with 0.05 < P ≤ 0.10 were considered tendencies. 
Results are presented as average and standard deviation (i.e. descriptive analyses of sequencing 
results) or least square means followed by the respective standard error of the mean. 
Multivariate analysis of microbiome data was carried out in R (R Core Team, Vienna, 
Austria) and QIIME. Beta diversity was analyzed through analysis of similarities (ANOSIM) 
using non-rarefied data normalized employing the packages metagenomeSeq (Paulson et al., 
2013) and vegan (Jari Oksanen, 2016) in R. Principal coordinate analysis (PCoA) was performed 
using weighted Unifrac distances calculated in QIIME and visualized through EMPeror 
(Vazquez-Baeza et al., 2013). 
RESULTS 
Clinical and Bacteriological Cure 
Intramammary treatment with ceftiofur hydrochloride did not significantly improve 
clinical and bacteriological cures of clinical mastitis compared with untreated controls (Table 
4.1). Of the 40 cows enrolled in the control group, 75% (n=30) experienced clinical cure, 
whereas of the 40 cows that received intramammary antibiotic therapy, 77.5% (n=31) 
experienced clinical cure (P-value = 0.79). Clinical cures for cows affected with Gram-negative 
intramammary infections also did not differ between the treated (75% cure rate) and control 
cows (73.9% cure rate) (P-value = 0.93). Bacteriological cure followed the same pattern as for 
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clinical cure, with 82.6% of the milk samples collected from non-treated mastitic quarters being 
negative on days 10 and 14 for the organism present on day 0, whereas in the treated group, 
79.2% of the samples were considered to be bacteriological cures (P-value = 1.00). 
Bacteriological cure was not altered by treatment when the data were stratified and analyzed by 
each pathogen group (Table 4.1). 
Real-time PCR Results  
Cows diagnosed with clinical mastitis caused by E. coli had a significantly (P=0.008) 
lower number of 16S rRNA gene copies in healthy quarters compared to mastitic ones on day 3 
post diagnosis; however, no difference was observed in the bacterial load as measured in 16S 
rRNA gene copies between healthy and mastitic quarters at days 8 and 14. Intramammary 
treatment with Ceftiofur caused a significant decrease in the bacterial load of mastitic quarters on 
day 3 (P = 0.01) compared to non-treated mastitic quarters. Nonetheless, a treatment effect was 
no longer observed at study day 8 (Figure 4.1a). 
In animals diagnosed with clinical mastitis yielding no bacterial growth upon aerobic 
culture, the number of 16S rRNA gene copies was higher in mastitic quarters compared to 
healthy ones. No treatment effect was observed on the bacterial load in this group of animals. 
Mastitic and healthy quarters exhibited the same bacterial load by study day 14 (Figure 4.1c). 
Sequencing Results  
Quality-filtered reads were demultiplexed and a total of 67,413,334 sequences was used 
for downstream analyses (mean=47,241.3 ± SD=32,625.0 reads/sample). The median length for 
all reads was 301 bp.  
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Microbiome Changes Associated with Clinical Mastitis 
The mean relative abundance of bacteria from the phylum Proteobacteria was greater (P 
< 0.01) in the milk from mastitic quarters infected by E. coli and Pseudomonas spp. compared 
with that of healthy quarters (Figure 4.2a-b). This was driven mostly by greater abundances of 
Enterobacteriaceae (P < 0.001; Figure 4.3) and Pseudomonadaceae (P = 0.03; Figure 4.S1). 
On the other hand, the average abundance of Firmicutes, Actinobacteria, Bacteroidetes, 
Tenericutes, Chlorobi, and the combination of all remaining phyla was greater (P < 0.05) in 
healthy compared with mastitic quarters infected by E. coli (Figure 4.2a). A similar pattern was 
observed in cows with clinical mastitis associated with Pseudomonas spp. (n = 2 quarters), in 
which the abundance of Actinobacteria and Bacteroidetes was greater (P < 0.05) and that of 
Chlorobi tended to be greater (P = 0.08) in healthy compared with mastitic quarters (Figure 
4.2b). The diversity of milk microbial populations was reduced (P < 0.0001) in E. coli mastitis 
compared with healthy quarters (Figure 4.1b). The Shannon index was also influenced (P < 
0.0001) by the interaction between mastitis and time, as values increased from day 1 through 14 
in mastitic quarters, whereas no change was observed in healthy counterparts (Figure 4.1b). 
Likewise, the richness of microbial communities was reduced in E. coli mastitis compared with 
healthy quarters (Figure 4.S2 a). 
The relative abundances of Firmicutes (P = 0.06) and the remaining phyla (P = 0.02) 
were greater in healthy quarters compared with those infected by Klebsiella spp. (Figure 4.2c). 
Nevertheless, mastitis did not affect the relative abundances of other phyla or individual families 
(Figure 4.S3). Clinical mastitis associated with Klebsiella spp. had reduced (P = 0.05) Shannon 
values shortly after diagnosis but had no effect on the Chao1 index (Figure 4.S4 a-b). 
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Shifts in the milk microbiome were less pronounced in cases of clinical mastitis 
associated with a negative aerobic culture (Figure 4.2d). The relative abundance of Firmicutes 
was higher (P = 0.08), whereas those of Bacteroidetes (P = 0.06), Tenericutes (P = 0.05), 
Spirochaetes (P = 0.01), and the combined remaining phyla (P = 0.08) were lower in mastitic 
quarters. Fluctuations in bacterial communities were not associated with specific families 
(Figure 4.4). Nevertheless, diversity was reduced (P < 0.01) in mastitic compared with healthy 
quarters (Figure 4.1d). The same trend was observed in the Chao1 richness index on the first 
two days after diagnosis of clinical mastitis (Figure 4.S2 b). 
Effect of Intramammary Antibiotic Therapy on the Milk Microbiome 
In cows diagnosed with clinical mastitis caused by E. coli, microbiome dynamics in 
healthy quarters did not change over time (Figure 4.5a). On the other hand, the relative 
abundance of Enterobacteriaceae decreased from study day 1 to 14 (62.6% vs. 9.7%), whereas 
the relative abundances of other families increased in mastitic quarters (Figure 4.5b). Changes in 
milk bacterial populations were not affected by intramammary therapy with ceftiofur 
hydrochloride (Figure 4.5b). Treatment and the interaction between treatment and time did not 
affect the relative abundance of Enterobacteriaceae (Figure 4.6a), or the Shannon (Figure 4.1c) 
and Chao1 (Figure 4.S2 a) indexes in mastitic quarters infected by E. coli.  
Similar patterns were observed in cows with clinical mastitis caused by Klebsiella spp., 
as intramammary therapy did not impact the milk microbiome or the relative abundance of 
Enterobacteriaceae (Figure 4.S5 and 4.S6). The only two cows diagnosed with clinical mastitis 
associated with Pseudomonas spp. presented an elevated abundance of Pseudomonadaceae on 
day 1 (44.3%), which was reduced until day 8 (3.3%) and then returned to initial values on day 
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14 (46.1%). Because both cows were assigned to receive intramammary infusion with ceftiofur 
hydrochloride, the effect of treatment on abundance of Pseudomonas spp. could not be assessed.  
Changes in the milk microbiome over time were not observed in cows affected by clinical 
mastitis associated with negative aerobic culture (Figure 4.7a). Moreover, intramammary 
treatment with ceftiofur hydrochloride in these quarters did not affect the milk microbiome 
(Figure 4.7b) or the measures of microbial diversity and richness (Figure 4.1d), (Figure 4.S2 
b). 
Microbiome Changes Associated With Clinical Mastitis Cure on the Mastitic Quarters 
of Cows with Mastitis Caused by Escherichia coli 
In cows diagnosed with clinical mastitis caused by E. coli, microbiome dynamics in 
mastitic quarters exhibited remarkable changes over time. Quarters that experienced clinical cure 
by the end of the study period had significantly lower abundances of Enterobacteriaceae family 
members in both control (Figure 4.6c) and treated animals (Figure 4.6e). Nevertheless, 
microbial diversity at diagnosis of clinical mastitis did not differ between quarters that eventually 
became cured or not (Figure 4.6b). However, microbial diversity of quarters that eventually 
were cured showed increasing microbial diversities in both the control (Figure 4.6d) and treated 
groups (Figure 4.6f) relative to quarters that did not show bacteriological cure during the study 
period. Similar patterns were observed for bacteriological cure (Figure 4.S7). 
Multivariate Analysis of Microbiome Data from Healthy and Mastitic Quarters 
Analysis of similarities revealed that mastitic quarters were significantly different from 
healthy quarters at the first day after diagnosis of clinical mastitis in cows with clinical mastitis 
associated with E. coli (Figure 4.8a), and negative culture (Figure 4.8b). A clear separation 
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between mastitic and healthy quarters was observed in the principal coordinate analysis of 
Unifrac distances in animals with clinical mastitis associated with E. coli (Figure 4.8a); however 
the same could not be observed in animals with mastitis associated with negative culture (Figure 
4.8b). At the end of the study, namely day 14 after diagnosis of clinical mastitis, the microbiome 
of quarters that had been cured from clinical mastitis did not differ from the one of healthy 
quarters in either ANOSIM or Unifrac PCoA in cows previously identified with clinical mastitis 
associated with E. coli (Figure 4.8e) nor in animals with clinical mastitis yielding negative 
aerobic culture (Figure 4.8f). Interestingly, when the microbiome of quarters that remained with 
abnormal milk by the end of the study was included in the analysis, a significant difference could 
be observed in both ANOSIM and Unifrac PCoA on the microbiome of milk from cows 
identified with clinical mastitis associated with E. coli (Figure 4.8c). No separation between 
mastitic, healthy, and cured quarters could be observed when the first three components of 
Unifrac PCoA were plotted in animals with mastitis associated with negative culture (Figure 
4.8d). 
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Figure 4.1. Effect of clinical mastitis and intramammary treatment with ceftiofur hydrochloride 
(days 1-5) on the number of 16S rRNA gene copies in cows with clinical mastitis associated with 
Escherichia coli (a) or negative culture (c), and microbial diversity in cows with clinical mastitis 
associated with Escherichia coli (b) or negative culture (d). Bars represent standard error of the 
mean. Asterisks represent significant differences at α = 0.05 between groups within the same 
study day. (a) Mastitic-Control had a significantly greater bacterial load than Mastitic-Ceftiofur 
and healthy quarters on day 3. (c) On day 1, both mastitic quarters had a significantly greater 
bacterial load when compared to healthy quarters. On day 8: Mastitic-Control had a significantly 
greater bacterial load than Mastitic-Ceftiofur and healthy quarters. 
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Figure 4.2. Relative abundance of phyla in quarters diagnosed with clinical mastitis (red bars) 
and healthy quarters (blue bars) according to identification of milk pathogens by laboratory 
culture. ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05, †P ≤ 0.10. Bars represent standard error of the mean. 
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Figure 4.3. Comparison of the microbiome from quarters with clinical mastitis associated with 
Escherichia coli and healthy quarters (i.e. reference for calculation of fold change). Size of the 
circle is proportional to the overall prevalence of each family. Color of the circle is associated 
with effect size. The graph plots log fold change in 16S rRNA gene abundance in mastitic 
relative to healthy control quarters versus false discovery rate (FDR) logWorth (i.e. -log10P). P-
values are adjusted for FDR. The dashed line represents the adjusted P-value = 0.01. 
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Figure 4.4. Comparison of the microbiome from quarters with clinical mastitis associated with 
negative culture and healthy quarters (i.e. reference for calculation of fold change) on day 0. Size 
of the circle is proportional to the overall prevalence of each family. Color of the circle is 
associated with effect size. The graph plots log fold change in 16S rRNA gene abundance in 
mastitic relative to healthy control quarters versus false discovery rate (FDR) logWorth (i.e. -
log10P). P-values are adjusted for FDR. The dashed line represents the adjusted P-value = 0.05. 
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Figure 4.5. Effect of intramammary treatment with ceftiofur hydrochloride on relative 
abundance of the 25 most prevalent families in milk from quarters with clinical mastitis 
associated with Escherichia coli. Numbers indicate day after diagnosis of clinical mastitis. 
 
 
 
98 
 
 
Figure 4.6. Effect of intramammary treatment with ceftiofur hydrochloride (day 1) or cure on the 
relative abundance of Enterobacteriaceae and Shannon diversity index in cows with clinical 
mastitis associated with Escherichia coli. (a) Effect of intramammary treatment with ceftiofur 
hydrochloride (day 1) on the relative abundance of Enterobacteriaceae in cows with clinical 
mastitis associated with E. coli. Effect of eventual clinical cure on the relative abundance of 
Enterobacteriaceae in cows with clinical mastitis associated with E. coli on control cows (c) and 
treated cows (e). Effect of cure on the Shannon index in cows with clinical mastitis associated 
with E. coli (b), on control cows (d) and treated cows (f). Asterisks represent significant 
differences at α = 0.05 between groups within the same study day.  
` 
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Figure 4.7. Effect of intramammary treatment with ceftiofur hydrochloride on relative 
abundance of the 25 most prevalent families in milk from quarters with clinical mastitis 
associated with negative culture. Numbers indicate day after diagnosis of clinical mastitis. 
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Figure 4.8. Principal coordinate analysis of weighted Unifrac distances and ANOSIM analysis 
comparing the microbiome data of samples from healthy and mastitic quarters on day 1 (a and b) 
and day 14 (c, d, e, and f). Samples from quarters with clinical mastitis associated with E coli are 
depicted in sections a, c and e. Samples from quarters with clinical mastitis associated with 
negative culture are shown in sections b, d, and f.  
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DISCUSSION 
In an endeavor to better understand the effect of a third-generation cephalosporin 
(ceftiofur) in Gram-negative and culture-negative bovine mammary infections, we used high-
throughput DNA sequencing to assess longitudinal changes in the microbiome of mastitic and 
healthy milk in a randomized clinical trial. Our data demonstrate that antimicrobial treatment did 
not significantly affect total bacterial load in the infected quarters by the end of the treatment 
period, nor was it able to increase the rate of pathogen clearance within the mammary gland. 
Moreover, this is the first study to document in depth the dynamics of the milk microbiota 
longitudinally using state-of-the art technology. 
Treatment with ceftiofur did not affect clinical or bacteriological cure and did not have 
long-lasting effects on the milk microbiome. Our results are in disagreement with those of 
Schukken et al. (2011), who reported 38% bacteriological cure in non-treated cows and 73% 
bacteriological cure in treated animals. Their 5-day intramammary treatment regime with 
ceftiofur resulted in a significant increase in bacteriological cure, particularly in animals infected 
with E. coli, whereas our results demonstrate no difference between treated and untreated 
animals in this aspect. However, our results are in agreement with those of a landmark study 
conducted by Lago et al. (2011), which demonstrated that selective antimicrobial treatment of 
mastitic cows can lead to a considerable reduction in antimicrobial use without any significant 
differences in days to clinical cure, bacteriological cure risk, new intramammary infection risk or 
treatment failure. In that study, cows diagnosed with mastitis associated with E. coli either 
received two intramammary doses of cephapirin sodium 12 hours apart or did not receive 
antimicrobial treatment. The investigators were not able to detect any differences between 
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treated and untreated animals in either clinical or bacteriological cures. It is important to 
acknowledge that the treatment applied in that study utilized a first-generation cephalosporin, 
which has a lower effectiveness against Gram-negative pathogens compared to ceftiofur 
(Schukken et al., 2013). 
Despite the observed effect of intramammary infusion of ceftiofur in reducing the total 
bacterial load measured by qPCR of the V4 region of the 16sRNA gene in the affected quarter on 
day 3, we failed to detect any differences between treated and untreated quarters at days 8 and 14 
post diagnosis. Furthermore, our data revealed that ceftiofur therapy had no effect on total 
bacterial load 3 days after cessation of treatment. We also assessed the longitudinal effect of 
antibiotic therapy on the relative abundance of the causal mastitis pathogens between treated and 
untreated cows; again, no differences were observed between the treatment and control groups. 
The observation that pathogen load was not affected by antimicrobial treatment is substantiated 
by a consistent decrease in the relative abundance of Enterobacteriaceae at 14 days post 
diagnosis in both treatment arms. Lastly, regardless of the treatment group, milk samples 
obtained on day 14 from all quarters deemed as mastitic on day 0 and that had normal milk on 
day 14 all presented a similar, more diverse bacterial profile, one remarkably comparable to that 
in healthy milk. Our data demonstrate that antimicrobial therapy does not improve cure rates for 
mastitis caused by E. coli, given the similar patterns of reduction in the percentage of pathogens 
over time in treated versus non-treated animals, which is in line with the results of Leininger et 
al. (2003) and the recommendations of Suojala et al. (2013). 
We have demonstrated how the microbiome of mastitic quarters associated with Gram-
negative pathogens dynamically changes over time. More interestingly, quarters that were not 
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cured by the end of the study period had diverging abundances of Enterobacteriaceae and 
microbial diversities over time when compared to mastitic quarters that became healthy by the 
end of the study period. Reduced bacterial diversity has also been reported in other studies 
comparing samples derived from healthy and diseased mammary environments (Oikonomou et 
al., 2012, Oikonomou et al., 2014, Jimenez et al., 2015). Although, most mastitis cases caused by 
E. coli are of an acute/peracute nature and have a high self-cure rate, chronic cases have been 
reported in the literature (Dogan et al., 2006, Fairbrother et al., 2015). Further research is needed 
to understand the host and pathogen idiosyncrasies that are associated with the chronification of 
these E. coli-related mastitis cases.  
Elucidating the milk microbiome has been a daunting task (Addis et al., 2016), 
particularly in clinical mastitis with negative culture results (Kuehn et al., 2013). Various reasons 
could explain why a negative result might be obtained from a mastitic milk culture: the 
microorganisms associated with the infection might be shed intermittently; or the number of 
viable bacterial cells are small; finally, the cow’s immune system might have eliminated the 
pathogen, and the observation of abnormal milk could be a consequence of the inflammatory 
process that occurred during destruction of the pathogen (Britten, 2012). Nevertheless, mastitis 
has also been reported to be caused by mechanical or chemical injury, as well as by non-bacterial 
infectious agents such as viruses (Wellenberg et al., 2002) and yeasts (Dworecka-Kaszak et al., 
2012). Although infrequent, it is important to acknowledge that a portion of these culture 
negative mastitis cases can be result of a viral infection playing a role in clinical mastitis. In fact, 
the historical role of viruses in mastitis might have been underestimated, given that the practice 
of laboratory diagnosis of viruses in mastitis cases is unusual (Wellenberg et al., 2002). 
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In our study, mastitic quarters yielding a negative aerobic result differed in bacterial load 
compared to their healthy counterparts. This is a very interesting finding, as we were not able to 
identify in the microbial profiles any specific bacterial family that could be associated with these 
mastitis cases. The identification of a higher bacterial load not linked to a specific group of 
pathogens might indicate that dysbiosis occurs not only with changes in the composition of the 
mammary microbiota, but also with a simple nonspecific increase of intramammary bacterial 
load, leading to clinical signs of mastitis. It is true that the number of 16S rRNA copies in the 
genome is variable, which can impact bacterial community analysis (Vetrovsky and Baldrian, 
2013); however, the quantification of 16S rRNA gene has been proved to be useful as a proxy for 
estimating bacterial load (Nadkarni et al., 2002). In our study, mastitic quarters exhibited 
significantly lower microbial diversity upon diagnosis compared to healthy quarters, which could 
indicate that fewer microbes were dominating the milk microbiome. Our results are in line with 
those of Kuehn et al. (2013), who identified that the microbiome of mastitic quarters is less 
diverse than healthy ones in culture-negative mastitis cases. Recent work by Falentin et. al. 
(2016) has raised an interesting discussion when it comes to microbial diversity, dysbiosis and 
disease. The investigators demonstrated that animals presenting normal milk at sampling, but 
with different histories in regards of clinical and subclinical mastitis had remarkably different 
bacterial diversity, as well as an altered microbial profile far from an episode of clinical mastitis. 
Research is warranted to determine the relationship between changes of the mammary 
microbiota and timing of clinical mastitis, and elucidate if a shift in the microbial profile 
predisposes to clinical mastitis, or if an active colonization of a rather normal microbiome is to 
be held accountable for both the clinical episode and the lasting effect on the alteration of the 
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milk microbiome. Koskinen et al. (2010) evaluated the use of a pathogen-specific real-time PCR 
assay for identification of mastitis bacteria and reported that 76% of culture-negative clinical 
mastitis samples were positive for various mastitis pathogens, including members of the 
Streptococci, Staphylococci and Enterobacteriaceae families. However, it has previously been 
reported that such bacteria are found in the microbiome of healthy milk of both humans and 
cows (Martin et al., 2007, Hunt et al., 2011, Oikonomou et al., 2014). Although infrequent, 
mastitis caused by different species of Mycobacterium has been reported in bovines, alpacas and 
dogs (Menard et al., 1983, Schultze and Brasso, 1987, Richey et al., 2011, Murai et al., 2013). 
Mycobacterium is often misidentified as a negative culture due to its slow growth characteristics 
and because it is a facultative anaerobic microbe (Menard et al., 1983, Franco et al., 2013). In 
our results, we observed a non-significant increase in the relative abundance of 
Mycobacteriaceae in mastitic animals yielding negative aerobic culture results. Identifying 
which microorganisms are associated with culture-negative mastitis does not justify the use of 
antimicrobial treatment; however, it does shed light on the bacterial etiology of the disease, 
facilitating decision-making regarding mastitis prevention strategies. 
Differences in the microbiome of healthy and mastitic milk samples have also been 
reported for cows (Oikonomou et al., 2012, Kuehn et al., 2013, Oikonomou et al., 2014) and 
humans (Hunt et al., 2011, Jimenez et al., 2015). However, a unique feature of the research 
presented here is that we used a controlled randomized clinical trial approach to longitudinally 
describe the differences between milk from mastitic mammary glands and from healthy ones and 
the impact of antibiotic therapy on the microbiome from the onset of disease until its resolution. 
To our knowledge, this is the first study to longitudinally evaluate the effect of antimicrobial 
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therapy using the combination of quantitative PCR and next-generation DNA sequencing in 
dairy cows. Bovine milk, similarly to human milk, exhibits a complex and dynamic microbial 
ecology (Hunt et al., 2011, Bhatt et al., 2012, Oikonomou et al., 2012, Kuehn et al., 2013, 
Oikonomou et al., 2014, Jimenez et al., 2015). Nevertheless, significant efforts have been 
recently undertaken using culture-independent techniques to evaluate the effects of antibiotic 
therapy in swine (Kim et al., 2016), horses (Costa et al., 2015), gorillas (Vlckova et al., 2016), 
and humans (Stressmann et al., 2012, Zhao et al., 2012, IHMP Research Network Consortium, 
2014, Lax et al., 2014, Zhou et al., 2015). 
Antimicrobial use in the food industry could potentially impact human health, warranting 
its judicious use (Wittum, 2012, van Helden et al., 2013). Ceftiofur is the only FDA-approved 
third-generation cephalosporin for use in food-producing animals and has been classified by the 
World Health Organization as one of the critically important antimicrobials for human medicine 
(WHO, 2012). In summary, our work corroborates the existing literature and also provides novel 
evidence that the use of intramammary ceftiofur therapy for the treatment of mild and moderate 
cases of E. coli-caused and culture-negative mastitis is ineffective. More importantly, it suggests 
that antimicrobial stewardship in food animals can be achieved in certain situations without 
compromising the health of the animals. Additionally, the combined use of quantitative PCR and 
sequencing of the 16s rRNA gene is an effective approach to evaluate the usefulness of antibiotic 
therapy. 
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SUPPLEMENTARY INFORMATION 
Figure 4.S1. Comparison of the microbiome from quarters with clinical mastitis associated with 
Pseudomonas spp. and healthy quarters (i.e. reference for calculation of fold change). Size of the 
circle is proportional to the overall prevalence of each family. Color of the circle is associated 
with effect size. The graph plots log fold change in 16S rRNA gene abundance in mastitic 
relative to healthy control quarters versus false discovery rate (FDR) logWorth (i.e. -log10P). P-
values are adjusted for FDR. The dashed line represents adjusted P-value = 0.05. 
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Figure 4.S2. Effect of clinical mastitis and intramammary treatment with ceftiofur hydrochloride 
on richness of the milk microbiome in cows with clinical mastitis associated with Escherichia 
coli (a) and in cows with clinical mastitis associated with a negative culture (b). 
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Figure 4.S3. Comparison of the microbiome from quarters with clinical mastitis associated with 
Klebsiella spp. and healthy quarters (i.e. reference for calculation of fold change). Size of the 
circle is proportional to the overall prevalence of each family. Color of the circle is associated 
with effect size. The graph plots log fold change in 16S rRNA gene abundance in mastitic 
relative to healthy control quarters versus false discovery rate (FDR) logWorth (i.e. -log10P). P-
values are adjusted for FDR. 
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Figure 4.S4. Effect of clinical mastitis and intramammary treatment with ceftiofur hydrochloride 
on diversity (a) and richness (b) of the milk microbiome in cows with clinical mastitis associated 
with Klebsiella spp. 
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Figure 4.S5. Changes in relative abundance of the 25 most prevalent families in milk from 
quarters with clinical mastitis associated with Klebsiella spp. and healthy quarters. Numbers 
indicate day after diagnosis of clinical mastitis. 
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Figure 4.S6. Effect of intramammary treatment with ceftiofur hydrochloride (day 1) on the 
relative abundance of Enterobacteriaceae in cows with clinical mastitis associated with 
Klebsiella spp. TRT = effect of treatment; Day = effect of time; T×D = interaction between 
treatment and day. 
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Figure 4.S7. Effect of intramammary treatment with ceftiofur hydrochloride (day 1) or cure on 
the relative abundance of Enterobacteriaceae and Shannon diversity index in cows with clinical 
mastitis associated with Escherichia coli. (a) Effect of intramammary treatment with ceftiofur 
hydrochloride (day 1) on the relative abundance of Enterobacteriaceae in cows with clinical 
mastitis associated with E. coli. Effect of eventual bacteriological cure on the relative abundance 
of Enterobacteriaceae in cows with clinical mastitis associated with E. coli on control cows (c) 
and treated cows (e). Effect of cure on the Shannon index in cows with clinical mastitis 
associated with E. coli (b), on control cows (d) and treated cows (f). Asterisks represent 
significant differences at α = 0.05 between groups within the same study day. 
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ABSTRACT 
The use of antimicrobials in food animals and the emergence of antimicrobial resistance 
are global concerns. Ceftiofur is the only third-generation cephalosporin labeled for veterinary 
use in the USA, and it is the drug of choice in the majority of dairy farms for the treatment of 
mastitis. Here, we use next-generation sequencing to describe longitudinal changes that occur in 
the milk microbiome before, during, and after infection and treatment with ceftiofur. Twelve 
animals were intramammary challenged with Escherichia coli in one quarter and randomly 
allocated to receive intramammary treatment with ceftiofur (5d) or untreated controls. Serial 
samples were collected from −72 to 216 h relative to challenge from the challenged quarter, an 
ipsilateral quarter assigned to the same treatment group, and from a third quarter that did not 
undergo intervention. Infection with E. coli dramatically impacted microbial diversity. Ceftiofur 
significantly decreased LogCFUs but had no significant effect on the milk microbiome, rate of 
pathogen clearance, or somatic cell count. At the end of the study, the microbial profile of 
infected quarters was indistinguishable from pre-challenge samples in both treated and untreated 
animals. Intramammary infusion with ceftiofur did not alter the healthy milk (i.e., milk devoid of 
lots or serous appearance and collected from a mammary gland that shows no clinical signs of 
mastitis) microbiome. Our results indicate that the mammary gland harbors a resilient 
microbiome, capable of reestablishing itself after experimental infection with E. coli independent 
of antimicrobial treatment. 
Keywords: Milk microbiome, Mastitis, E. coli, Ceftiofur, Dairy cattle, Antimicrobial 
treatment, Milk, Third-generation cephalosporin, Cephalosporins 
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INTRODUCTION 
Mastitis is a prevalent, costly (Heikkila et al., 2012, Rollin et al., 2015) disease in dairy 
cows that is defined by increase in milk somatic cell count (SCC) as a result of inflammation in 
the mammary gland, leading to abnormal milk and varying degrees of clinical severity. This 
condition affects almost 25% of the 9.3 million dairy cows present in the United States every 
year (USDA, 2016), and negatively impacts animal welfare (Medrano-Galarza et al., 2012, 
Fogsgaard et al., 2015, Peters et al., 2015) and productivity (Grohn et al., 2004, Bar et al., 2008, 
Schukken et al., 2009). Recent studies have reported that approximately 80% of all 
antimicrobials used on American dairy farms are for the treatment or prevention of mastitis (Pol 
and Ruegg, 2007). Prevention measures, improved management, and sanitation have reduced the 
number of contagious mastitis cases and have led to a change in the etiology of the disease in the 
last decade (Bushnell, 1984, Jones, 2012, USDA, 2016), making opportunistic environmental 
pathogens, including coliforms, major contributors to clinical mastitis. 
Antimicrobial resistance is a global concern and has led to increasing attention regarding 
the judicious use of antibiotics. Although conflicting evidence is available on whether human, 
companion, and/or livestock medicine is responsible for the emergence of antimicrobial 
resistance (Ma et al., 2016, Pal et al., 2016), the livestock industry has been recognized as one of 
the main causes (Pal et al., 2016, Pitta et al., 2016); perhaps due to the amount of antimicrobials 
used in this sector (Muziasari et al., 2016), affecting humans either through direct contact or 
through the food chain (Singer et al., 2003, Lhermie et al., 2016). The increasing demand for 
animal protein is believed to be accompanied by a significant growth in need for antimicrobial 
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use in food animal production, which is predicted to rise by approximately 67% between 2010 
and 2030 (Lhermie et al., 2016). Responsible use of antimicrobials in food animals is paramount 
for maintenance of both animal and human health (FDA, 2017) and has been one of the policies 
proposed by the One Health Initiative (The One Health Initiative, van Helden et al., 2013, Dar et 
al., 2016). Ceftiofur is the only third generation cephalosporin labeled for veterinary use in the 
United States (USDA, 2016), is considered a critically important antimicrobial for human 
medicine (WHO, 2012), and is the drug of choice in the majority of dairy operations for 
intramammary treatment of mastitis (USDA, 2016). To this date, the effectiveness of the 
treatment of coliform mastitis has been discussed in an ambiguous manner (Schukken et al., 
2011a, Suojala et al., 2013). Nevertheless, all information regarding the effectiveness of 
antimicrobial therapy reported so far is based on clinical cure and the ability to isolate and 
culture a specific pathogen from a mastitic milk sample in a laboratory setting. Culture 
independent studies resulted in significant proof for the existence of a resident microbiota in milk 
in humans (Hunt et al., 2011, Boix-Amoros et al., 2016), bovines (Bhatt et al., 2012, Oikonomou 
et al., 2012, Lima et al., 2017), and other species (Quigley et al., 2013). In light of constantly 
advancing molecular techniques, the use of next generation sequencing led to a paradigm shift in 
the understanding of the dynamics of health and disease (Oikonomou et al., 2014, Falentin et al., 
2016) and offers an opportunity to provide evidence that will substantiate antibiotic stewardship, 
helping the optimization of preventative, diagnostic, and treatment protocols for bovine mastitis. 
Therefore detailed information on the effect of treatment of Escherichia coli mastitis with third 
generation cephalosporins is indispensable. 
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Our group has recently described the dynamics of milk microbiome upon antimicrobial 
treatment with ceftiofur in animals naturally infected with mastitis pathogens (Ganda et al., 
2016). In that study, cows from a commercial dairy farm were enrolled upon diagnosis of clinical 
mastitis and randomly allocated to receive extended intramammary therapy with ceftiofur, or to 
receive no treatment. We observed that in cows with mastitis caused by E. coli, treatment with 
ceftiofur did not offer an advantage when compared to no treatment in terms of clinical cure, 
pathogen clearance rate, or bacterial load. Moreover, the milk microbiome from the affected 
quarters was indistinguishable from the adjacent healthy quarters within 14 days following the 
onset of the disease regardless or intramammary antimicrobial administration.  
Herein we describe a challenge model using a known strain of mastitis-causing E. coli to 
characterize the microbiome before, during, and after intramammary infection in a controlled 
setting. We aim to investigate the changes that occur upon introduction of a major pathogen, and 
the ability of the healthy mammary microbiota to restore equilibrium with or without external aid 
of antimicrobials. Moreover, the role of antimicrobials in the normal milk microbiota has not yet 
been investigated in controlled longitudinal studies. We hypothesize that intramammary 
administration of a broad-spectrum antimicrobial might favor the overgrowth of specific 
organisms and incite a shift in the microbial profile of milk from normal quarters. 
Therefore, the objectives of this study were to generate knowledge on the complex 
microbial ecology and treatment of mastitis, more specifically: a) describe the milk microbiome 
before, during, and after the infection of bovine mammary glands with a strain of E. coli 
previously isolated from a mastitis case; b) compare microbial populations between infected and 
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uninfected quarters, and c) evaluate the impact of a third generation cephalosporin on both 
healthy and mastitic milk. 
MATERIALS AND METHODS 
Ethics Approval 
All experimental procedures were carried out at Cornell University, according to a 
research protocol that was reviewed and approved by the Cornell University Institutional Animal 
Care and Use Committee (protocol number 2013-0056). 
Challenge Strain 
The strain used in this study (E. coli ECC-Z, Cornell University) (Dogan et al., 2006) 
hereafter referred as C1, was isolated from a clinical case of bovine mastitis, and was proven 
effective in previous experimental challenges to result in mild to moderate cases of clinical 
mastitis (Quesnell et al., 2012, Sipka et al., 2013). Before experimental challenge, frozen stocks 
of the strain were activated in Luria-Bertani (LB) broth, incubated at 37°C for 12h and 
subsequently streaked on a McConkey plates for E. coli colony isolation. DNA extraction was 
performed in isolated colonies using a QIAamp DNA minikit (Qiagen Inc., Valencia, CA), and a 
fragment of the 16S rRNA gene was amplified using the primers 27F (5’-
AGAGTTTGATCMTGGCTCAG-3’) and 1492R (5’-ACCTTGTTACGACTT-3’), followed by 
sequencing at the Cornell University Core Laboratories Center (Ithaca, NY) through Sanger 
sequencing for confirmation of the identity of the isolate. 
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Animal Selection and Housing 
Twelve mature (second or greater lactation) Holstein cows were selected from the 
Cornell Veterinary Medicine Teaching Dairy (Ithaca, NY). Six animals, two at a time, were 
challenged during March of 2014, and six animals were challenged two at a time between March 
and April of 2015. Experimental challenge and sampling took place at the Large Animal 
Teaching and Research Unit (LARTU), Department of Animal Sciences, Cornell University 
(Ithaca, NY). Selected animals had no previous cases of clinical mastitis in the current lactation, 
were between 246 and 461 days in milk, and had an average somatic cell count of 95,000 
cells/mL, ranging from 41,000 cells/mL to 191,000 cells/mL, measured one week prior to 
transportation to LARTU. 
Animals were housed individually in stalls bedded with sawdust, and were fed ad libitum 
the same diet provided at the farm from which they were sourced, calculated to meet or exceed 
the requirements for lactating Holstein cows with a body weight of 650 kg producing 45kg of 
3.5% fat corrected milk. The feed was transported daily from the Cornell Teaching Dairy. 
Animals were milked twice daily, at 08:00 and 20:00.  
Sampling Procedures and Experimental Infection 
Sampling scheme, treatment allocation, and experimental design are depicted in (Figure 
5.1a,b). Milk samples were collected every 12 hours during the three days that preceded 
intramammary infection with E. coli strain C1, henceforth indicated as time 0, and every six 
hours from live challenge with E. coli until the 9th day after infection, with the last time point 
being at 216 hours post-challenge. Only one quarter was challenged: 100 colony forming units 
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(CFU) of E. coli C1 suspended in 1mL of phosphate buffered saline (PBS) solution was 
deposited immediately ventral of the Furstenberg’s rosette via the teat canal. 
Each animal had three quarters sampled at each time point: the challenged quarter, an 
ipsilateral unchallenged quarter that was included in the same antibiotic treatment group as the 
challenged one, and a third quarter which did not undergo any intervention (i.e. no challenge, no 
treatment) and was sampled in every time point as a within-animal control. Before milk sample 
collection, each cow had teats dipped in iodine (Bovadine sanitizing teat dip, DeLaval 
Manufacturing, Kansas City, MO), which was left in contact for at least 30 seconds. Teats were 
wiped with dry sterile gauze and final teat disinfection was performed with gauze soaked in 70% 
(v/v) ethanol immediately prior to collection of the milk sample. The three initial streams of milk 
were discarded; milk was collected into sterile tubes in three different aliquots and immediately 
placed on ice. The first aliquot was collected and kept frozen at -20°C until DNA extraction, the 
second aliquot was used for CFU counting, and a third aliquot was submitted for SCC 
determined through flow cytometry (Fossomatic FC, Eden Prairie, MN) at the Dairy One 
Cooperative Inc. (Ithaca, NY). Linear score (LS) was calculated based on SCC according to the 
equation LS = [ln(SCC/105)/ln(2)] + 3. Health status and temperature of each cow were assessed 
at each sampling time, and cows showing signs of systemic illness were provided with 
appropriate supportive therapy, which included intravenous administration of fluids and 
intramuscular administration of non-steroidal anti-inflammatory drugs.  
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Treatment Administration 
At 48 hours after infection, animals were randomly allocated into either the treatment 
group, which received five consecutive intramammary infusions of ceftiofur hydrochloride 
comprised of 125 mg of ceftiofur equivalents (as ceftiofur hydrochloride; Spectramast LC®, 
Zoetis, Florham Park, NJ) at 24-hour intervals in both challenged and ipsilateral unchallenged 
quarters, or the untreated control group, for which no substance was introduced into the 
mammary glands. The timing of first treatment was chosen in an attempt to mimic the dynamics 
of culture-based treatment of coliform mastitis in a commercial dairy farm, and the first dose was 
administered immediately after sample collection of the 48-hour sample. 
 
CFU Counting and Strain Typing 
Milk samples collected at time points following intramammary infection were inoculated 
on MacConkey agar in 100 µL aliquots and incubated at 37°C overnight for bacterial 
identification. Total CFU/mL was calculated based on quantitative culture of serial milk 
dilutions in triplicates by averaging the number of colonies in the triplicate and multiplying the 
number by the dilution factor.  
Strain typing was performed through random amplification of polymorphic DNA 
(RAPD) with primers designed specifically for RAPD typing of Gram negative bacteria 
(forward: 5’-AGTAAGTGACTGGGGTGAGCG-3’, reverse: 
5’TACATTCGAGGACCCCTAAGTG-3’), which have been shown to discriminate between 
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different strains of mastitis-causing E. coli (Dogan et al., 2006). PCR products were evaluated 
for banding pattern using gel electrophoresis in a 1.5% agarose gel at 60V for 1.5 h. 
DNA Isolation and Purification 
Genomic DNA extraction was performed using the PowerFood DNA Isolation Kit (MO 
BIO Laboratories Inc., Carlsbad, CA), following the manufacturer’s recommendations with an 
extra incubation at 65°C for 10 minutes prior to cell disruption to maximize DNA yields 
(Quigley et al., 2012). A six mL aliquot of milk was divided into fat, whey, and pellet through 
centrifugation. Whey was discarded and the fat layer and pellet were used as starting sample in 
DNA extraction, as described previously (Ganda et al., 2016). Concentration and purity of 
isolated DNA were evaluated based on optical density at 230, 260 and 280 nm wavelengths 
(NanoDrop ND-1000, NanoDrop Technologies, Wilmington, DE). 
16S rRNA Gene Amplification, MiSeq Sequencing, and Bioinformatic Analyses 
Isolated genomic DNA was used as a template for amplification of the V4 hypervariable 
region of the bacterial 16S rRNA gene using the primers 515F and 806R, which had been 
optimized for the Illumina MiSeq platform (Illumina Inc., San Diego, CA) (Caporaso et al., 
2012) as described previously (Foditsch et al., 2015). 
Six runs of the Illumina MiSeq sequencer were needed for sequencing of all samples. In 
each run, 279 samples and a sequencing control were pooled in an equimolar library and 
sequenced using the MiSeq reagent kit V2 for 300 cycles. Bioinformatics was performed using 
quality-filtered indexed reads, which were concatenated into a single FASTA file and uploaded 
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in the open-source pipeline Quantitative Insights into Microbial Ecology (QIIME) version 
1.9.1(Caporaso et al., 2010b), using computer resources of the Cornell Boyce Thompson 
Institute (Ithaca, NY). Sequences were handled following the default settings of the pipeline. 
Quality filtering was performed as described previously (Bokulich et al., 2013). Open-reference 
taxonomic assignment into operational taxonomic units (OTUs) with 97% identity was achieved 
using UCLUST (Edgar, 2010), RDP classifier (McDonald et al., 2012), PyNAST (Caporaso et 
al., 2010a), and the Greengenes (DeSantis et al., 2006) reference database. Rare OTUs with less 
than 5 sequences in each run, and samples with less than 1000 reads were excluded from the 
database. Within sample diversity (α-diversity) was assessed through Shannon diversity index 
calculated in a randomly selected subset of the OTU database obtained through the script 
single_rarefaction.py in QIIME at a rarefication level of 1,500 reads per sample. Between 
samples microbial diversity (β-diversity) was assessed through phylogenetic-based weighted 
UniFrac (Lozupone and Knight, 2005) distances, calculated in QIIME through the script 
beta_diversity.py and the distance matrix obtained was used for comparison between groups. 
Statistical Analyses 
The UNIVARIATE procedure of SAS version 9.4 (SAS Institute Inc., Cary, NC) was 
used to perform descriptive analyses. Non-normally distributed variables (i.e. SCC and CFU) 
were normalized through log transformation. Longitudinal changes in the microbial profile was 
assessed through description of the relative abundances of the 25 most abundant bacterial 
families using the tabulate function of JMP Pro 12 (SAS Institute Inc., Cary, NC), and relative 
abundances of all remaining families were combined into a single cluster, defined as ‘Other’. 
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Variables of interest were evaluated between challenged, unchallenged, treated, and untreated 
quarters with repeated measures ANOVA using the GLIMMIX procedure of SAS. Significance 
of pairwise comparisons were adjusted through the Tukey-Kramer multiple comparison 
correction. Outcomes were the relative abundance of Enterobacteriaceae, Shannon diversity 
index, LogSCC, LS, and LogCFUs; explanatory variables were challenge (challenged versus 
control quarter), treatment (treated versus untreated quarter), time relative to experimental 
challenge, and their two- and three-way interactions. 
To assess the effect of treatment, stratified analysis of covariance was performed in 
challenged and unchallenged quarters separately. To account for possible differences that 
occurred between intramammary infection and first treatment at 48h, the average of values 
observed between challenge and treatment (i.e. 0, 6, 12, 24, 36, 42, and 48 hours relative to 
challenge) was included as a covariate in these models. Variables of interest were the relative 
abundance of Enterobacteriaceae, Shannon diversity index, LogSCC, LS, and LogCFUs; 
explanatory variables were treatment (treated versus untreated quarter), time relative to 
experimental challenge, and their two-way interactions. Teat nested within cow was considered a 
random effect in all statistical models. The first-order ante-dependence covariance structure was 
selected because it resulted in the smallest Schwarz’s Bayesian information criterion value. 
Differences with P ≤ 0.05 were considered significant. Descriptive analyses of sequencing 
results are presented as average and standard deviation. All other results are presented as least 
square means followed by the respective standard error of the mean. 
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Three animals (animals E, G, and J – Additional file 1) experienced elevated SCC on the 
three days preceding intramammary infusion of bacteria and for that reason did not develop an 
infection following the challenge with E. coli. A fourth animal animal (animal L – Additional 
file 1) acquired a natural intramammary infection in one of the unchallenged quarters caused by 
an E. coli strain different from the experimental challenge strain. Data collected from these four 
animals was only used to compare challenged infected versus challenged, not infected quarters. 
All other analysis assessing the effect of experimental infection and treatment with ceftiofur did 
not include data from animals E, G, J, and L. 
Data were handled as follows: samples without a SCC value due to clotted milk (i.e. 
clinical mastitis) received a value of 30,000,000 SCC; samples with a CFU value that indicated 
too numerous to count received a value of 60,000 CFU. The rationale for choosing these 
arbitrary values was to assign a number that was larger than the largest observation for that 
variable in the dataset (i.e. largest SCC observed was 27,255,000 and largest CFU observed was 
58,000). 
Multivariate analysis of milk microbiome was implemented in QIIME and R (R Core 
Team, Vienna, Austria). Analysis of Similarities (ANOSIM) was performed in non-rarefied data 
using the vegan (Jari Oksanen, 2016) package in R. Groups shown to be significantly different in 
ANOSIM underwent Analysis of Composition of Microbiomes (ANCOM) (Mandal et al., 2015) 
carried out in QIIME version 2.0.6 (Caporaso et al., 2010b), in an attempt to identify which 
OTUs were driving the main differences between groups. Microbiome changes over time in 
challenged and control quarters were visualized through Principal Coordinates Analysis (PCoA) 
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of weighted UniFrac distances calculated in QIIME and plotted using EMPeror (Vazquez-Baeza 
et al., 2013). 
RESULTS 
Health Characteristics 
All cows exhibited elevated rectal temperature (Mean 39.1°C, StdDev 0.9°C) at 18h post-
challenge (Figure 5.1c); one animal had recurrent fever and received support therapy as 
described above. 
Abnormal milk was observed within 18 hours of infection (i.e. presence of flakes, clots, 
or serous milk) and lasted until 132 and 192 hours in control and ceftiofur groups, respectively. 
Mild clinical signs of mammary inflammation were observed, which included abnormal milk 
and/or redness and swelling of the challenged quarters (Figure 5.1d). 
 
 
Bacterial Isolation and Strain Typing 
The C1 strain of E. coli used for intramammary infection was isolated from milk samples 
collected post-challenge from every challenged quarter, except the three quarters that presented 
elevated SCC on the days preceding intramammary infusion of bacteria, which were excluded 
from further analysis. Confirmation of strain was performed through RAPD strain typing 
(Figure 5.1e).  
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Effect of Intramammary Infection with E. coli and Intramammary Antimicrobial 
Therapy on CFU Results 
Intramammary infection with E. coli significantly increased LogCFUs (P<0.0001); 
intramammary treatment with ceftiofur significantly decreased LogCFUs in challenged, infected 
quarters (P<0.0001). Tukey-adjusted comparisons in each sampling time revealed that ceftiofur-
treated quarters had significantly lower LogCFUs at 78, 84, 102, 108, 120, 126, 132, 144, and 
150 hours relative to challenge (Figure 5.1f). Nevertheless, bacterial growth in samples collected 
from both control and treated quarters presented a decrease in CFU counts over time. 
Effect of Intramammary Infection with E. coli on Somatic Cell Count Measured as 
Linear Scores 
Intramammary infusion with 100 CFU of E. coli increased SCC as early as six hours 
post-challenge, peaking around 18 hours and remaining significantly higher when compared to 
unchallenged quarters until the end of the study period (P<0.0001) (Figure 5.2b). A non-
significant increase in somatic cell count on unchallenged quarters was also observed between 12 
and 48 hours relative to challenge (Figure 5.2d). Finally, intramammary treatment with ceftiofur 
hydrochloride did not significantly decrease linear score throughout treatment, with only two 
time points exhibiting different linear scores between treated and untreated groups (Figure 5.2c). 
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Sequencing Results 
A total of 53,019,538 sequences passed quality control and were available for 
downstream analysis. The dataset analyzed, which only included infected animals, comprised 
34,193,997 reads with a mean of 39,622 and standard deviation of 31,034 reads per sample. 
Taxonomic Classification  
On average, only 22.2% of all reads were not classified at the family level (StdDev 
19.3%), whereas the number of unclassified reads at the genus level was on average 50.6% 
(StdDev 23.7%). The most abundant families in the dataset were Ruminococcaceae (Mean 
13.5% StdDev 12.0%) Enterobacteriaceae (Mean 13.4% StdDev 24.6%), Aerococcaceae (Mean 
5.6%, StdDev 7.7%), Lachnospiraceae (Mean 5.4%, StdDev 5.4%), Corynebacteriaceae (Mean 
5.2%, StdDev 6.5%), Planococcaceae (Mean 5.2%, StdDev 7.9%), Bacillaceae (Mean 4.7%, 
StdDev 5.9%), Clostridiaceae (Mean 4.5%, StdDev 3.9%), Bacteroidaceae (Mean 4.2%, StdDev 
3.6%), and Staphylococcaceae (Mean 3.6%, StdDev 6.5%). Detailed information on bacterial 
profile per study animal is provided in the supplementary information. 
Pre-Challenge Microbial Profile 
The microbial profile prior to intramammary infusion of E. coli (-72h to 0h) was diverse 
(Figure 3). No differences were observed between challenged, unchallenged, treated, and 
untreated groups in the pre-challenge microbiome. The most abundant families in pre-challenge 
samples were Ruminococcaceae (Mean 16.8%, StdDev 10.1%), Lachnospiraceae (Mean 7.0%, 
StdDev 5.1%), Aerococcaceae (Mean 6.8%, StdDev 8.2%), Enterobacteriaceae (Mean 6.3%, 
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StdDev 13.5%), Planococcaceae (Mean 5.7%, StdDev 9.5%), Bacteroidaceae (Mean 5.4%, 
StdDev 3.3%), Corynebacteriaceae (Mean 5.1%, StdDev 7.3%), Clostridiaceae (Mean 4.2%, 
StdDev 3.1%), Bacillaceae (Mean 3.5%, StdDev 3.7%), and Staphylococcaceae (Mean 2.8%, 
StdDev 4.9%). 
Effect of Experimental Infection with E. coli and Intramammary Antimicrobial 
Therapy on Milk Microbiome 
Intramammary infection with E. coli dramatically changed the milk microbial profile. 
Before challenge, quarters presented a very diverse profile, with the family Ruminococcaceae 
being the most abundant, averaging 13.3% and 14.3% in challenged untreated and challenged 
ceftiofur groups, respectively (Figure 5.3c,d). After experimental infection with E. coli, the milk 
microbiome had a significant increase in the family Enterobacteriaceae (P<0.0001) (Figure 
5.4b), which represented over 30% of the relative abundance from 12 to 150 hours, peaking at 
64.7% at 12 hours post-challenge in the untreated group (Figure 5.3c). Likewise, animals that 
eventually received intramammary treatment had Enterobacteriaceae as the predominant group, 
representing over 30% of the relative abundance from 12 to 60 hours, peaking at 77.9% at 18 
hours (Figure 5.3d). Intramammary treatment with ceftiofur hydrochloride did not significantly 
improve the clearance rate of Enterobacteriaceae, nor significantly decreased the relative 
abundance of Enterobacteriaceae in any time point when compared to challenged untreated 
quarters (Figure 5.4c). 
The microbial profile of unchallenged quarters was more diverse than what was observed 
in the post-infection challenged quarters (Figure 5.3). There was no remarkable change in the 
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relative abundances of the 25 most abundant families with intramammary treatment of 
unchallenged quarters with ceftiofur (Figure 5.3b).  
Effect of Experimental Infection with E. coli and Intramammary Antimicrobial 
Therapy on Bacterial Diversity 
Shannon diversity index was high and similar in all groups previous to experimental 
infection (Figure 5.5a). Diversity levels sharply decreased after experimental challenge with E. 
coli (P<0.0001), and the lowest diversity was observed between 30 and 78 hours post infection 
(Figure 5.5a,b). Administration of five doses of ceftiofur in 24-hour intervals starting at 48hours 
post-infection did not alter bacterial diversity in a consistent manner; Differences were observed 
in the diversity indexes before initiation of treatment regimen (at 36 and 48 hours). Nevertheless, 
Tukey-adjusted comparisons revealed that ceftiofur-treated animals had significantly different 
diversity indexes at 78, 102, and 180 hours relative to challenge (Figure 5.5c). By the end of the 
study period, treated and untreated quarters did not present significantly different diversity 
(Figure 5.5c). 
Unchallenged quarters presented high and stable diversity indexes throughout the study 
(Figure 5.5a,d). No difference was observed in diversity levels in unchallenged quarters 
between control and ceftiofur infused quarters. 
Effect of Pre-challenge Linear Scores on Intramammary Infection with E. coli  
Animals that were challenged with 100 CFU of E. coli and were successfully infected 
had significantly lower linear scores in all time points preceding challenge when compared to 
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cows that were found not to be infected with the strain C1 (Figure 5.6a). Animals infected with 
the challenge strain presented a sharp rise in LS as soon as 18 hours after challenge, and 
sustained higher LS throughout the study period when compared to challenged and not infected 
quarters (Figure 5.6a). The microbial profile of not infected quarters only had an increase in the 
relative abundance of the family Enterobacteriaceae representing 19% of the microbial profile at 
the 12 hour time point post challenge (Figure 5.6b), whereas infected quarters had their milk 
microbiome dominated by the family Enterobacteriaceae which represented over 75% of the 
relative abundance at the 12 hour time point post challenge and accounted for over 30% of the 
microbial profile until 132 hours post challenge (Figure 5.6c). 
Multivariate Analysis of Milk Microbiome and Effect of Intramammary Antimicrobial 
Therapy 
The relative abundance of the family Enterobacteriaceae was the main driver of the 
variation on weighted UniFrac distances in the dataset comprised of all samples from infected 
cows (Figure 5.7a). Samples from challenged quarters were discretized into seven categories 
according to time relative to experimental challenge, as well as treatment group. A significant 
difference in the milk microbiome was detected between the seven categories in ANOSIM, 
which was corroborated by clustering observed in weighted UniFrac PCoA (Figure 5.7b). 
Analysis of composition of microbiomes identified ten OTUs that significantly differed between 
groups, four of which were assigned to the family Enterobacteriaceae, one was assigned to the 
family Planococcaceae and five OTUS were not taxonomically assigned at the family level. 
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Stratified ANOSIM revealed a significant difference when the microbiome pre-challenge 
(-72 to 0h) was compared to post-challenge pre-treatment (6h to 48h). Grouping was observed in 
weighted UniFrac PCoA, with the family Enterobacteriaceae being the main driver of variation 
in this comparison (Figure 5.8a). Seven OTUs were deemed significantly different between 
groups in ANCOM, two of which were assigned to the family Enterobacteriaceae and five of 
which were not taxonomically assigned at the family level.  
The microbiome of samples from challenged treated and challenged untreated quarters 
were compared through ANOSIM before initiation of treatment (6h to 48h) and during treatment 
administration (54h to 150h). No differences were detected between treatment and control group 
in either ANOSIM or weighted UniFrac PCoA before initiation of treatment (Figure 5.8b) or 
during treatment administration (Figure 5.8c). When the microbiome of pre-challenge samples 
was compared to the of samples collected after treatment cessation (156 to 216h) through 
ANOSIM no significant differences were identified, which was corroborated through lack of 
grouping in weighted UniFrac PCoA (Figure 5.8d). In an attempt to identify if quarters that 
were not successfully infected after experimental infection had a different pre-challenge 
microbiome from quarters that were successfully infected, we performed ANOSIM in pre-
challenge samples. No difference was observed on the milk microbiome prior to experimental 
infection between challenged infected and challenged uninfected quarters (ANOSIM: R= -0.17, 
P=0.99). In agreement with ANOSIM, PCoA of weighted UniFrac distances did not reveal any 
clustering pattern (data not shown). All samples from an individual animal were sequenced in 
order within a run; batch effects that could have arisen due to samples being sequenced in six 
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different runs were examined through weighted UniFrac PCoA, and no clustering due to 
sequencing run was observed (data not shown). 
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Figure 5.1. Experimental challenge timeline (a). Schematic of challenge and treatment in each 
quarter (b), effect of intramammary infection with E. coli and treatment with ceftiofur 
hydrochloride (48, 72, 96, 120, and 144 hours) on Temperature (c), California Mastitis Test 
(CMT) results (d). RAPD strain typing results (e) effect of intramammary infection with E. coli 
and treatment with ceftiofur hydrochloride (48, 72, 96, 120, and 144 hours) on Colony Forming 
Units (CFU) (f). Asterisks represent differences after Tukey-Kramer multiple comparison 
correction and α=0.05 between groups within the same time point. 
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
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Figure 5.2. Effect of experimental infection with Escherichia coli (0 h) and intramammary 
treatment with ceftiofur hydrochloride (48, 72, 96, 120, and 144 h) on Linear Scores. Effect of 
challenge and treatment (a, N(=(24 quarters), effect of intramammary challenge with Escherichia 
coli (b, N(=(24), stratified analysis of covariance assessing the effect of intramammary treatment 
with ceftiofur hydrochloride in challenged (c, N(=(8), and unchallenged quarters 
(d, N(=(16). Asterisks represent differences after Tukey-Kramer multiple comparison correction 
and α(=(0.05 between groups within the same time point. Black diamonds represent experimental 
infection with 100 CFU of E. coli, and grey circles represent intramammary treatment with 
ceftiofur. 
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Figure 5.3. Effect of intramammary infection with E. coli and subsequent treatment with 
ceftiofur hydrochloride (48, 72, 96, 120, and 144 h) on relative abundance of the 25 most 
prevalent families in unchallenged untreated quarters (a, N(=(11), in unchallenged ceftiofur-
infused quarters (b, N(=(5), in challenged untreated quarters (c, N(=(3), and in challenged and 
ceftiofur-treated quarters (d, N(=(5). Black diamonds represent experimental infection with 
100 CFU of E. coli, and grey circles represent intramammary treatment with ceftiofur. 
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Figure 5.4. Effect of experimental infection with Escherichia coli (0 h) and intramammary 
treatment with ceftiofur hydrochloride (48, 72, 96, 120, and 144 h) on relative abundance 
of Enterobacteriaceae. Effect of challenge and treatment (a, N(=(24 quarters), effect of 
intramammary challenge with Escherichia coli (b, N(=(24) and stratified analysis of covariance 
assessing the effect of intramammary treatment with ceftiofur hydrochloride in challenged 
(c, N(=(8) and unchallenged quarters (d, N(=(16). Asterisks represent differences after Tukey-
Kramer multiple comparison correction and α(=(0.05 between groups within the same time 
point. Black diamonds represent experimental infection with 100 CFU of E. coli, and grey 
circles represent intramammary treatment with ceftiofur. 
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Figure 5.5. Effect of experimental infection with Escherichia coli (0 h) and intramammary 
treatment with ceftiofur hydrochloride (48, 72, 96, 120, and 144 h) on Shannon diversity index. 
Effect of challenge and treatment (a, N(=(24 quarters), effect of intramammary challenge 
with Escherichia coli (b, N(=(24) and stratified analysis assessing the effect of intramammary 
treatment with ceftiofur hydrochloride in challenged (c, N(=(8) and unchallenged quarters 
(d, N(=(16). Asterisks represent differences after Tukey-Kramer multiple comparison correction 
and α(=(0.05 between groups within the same time point. Black diamonds represent experimental 
infection with 100 CFU of E. coli, and grey circles represent intramammary treatment with 
ceftiofur. 
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Figure 5.6. Effect of pre-challenge linear scores on intramammary infection success (a). 
Depiction of the relative abundance of the 25 most prevalent families in challenged uninfected 
quarters (b, N(=(3), and challenged and infected quarters (c, N(=(8). Black diamonds represent 
experimental infection with 100 CFU of E. coli. 
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Figure 5.7. Biplot depicting weighted UniFrac distances of all samples and the coordinates of 
the five most abundant family-level taxa (orange spheres) in the context of relative abundance 
of Enterobacteriaceae (a). Analysis of similarity (ANOSIM) and principal coordinate analysis 
(PCoA) of weighted UniFrac distances comparing the effect of challenge, treatment and time in 
challenged quarters only (b). For comparison and plotting purposes, time points were discretized 
into seven categories. 
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Figure 5.8. Multivariate analysis of milk microbiome. Effect of intramammary infection 
with E. coli on UniFrac distances and depiction of the five most abundant family-level taxa. 
Analysis of similarity (ANOSIM) and principal coordinate analysis (PCoA) of weighted UniFrac 
distances comparing pre-challenge (−72 to 0 h) and post-challenge (6 to 48 h) samples (a). 
Weighted UniFrac distances and ANOSIM comparing control and ceftiofur before initiation of 
treatment (b) and during treatment (c). ANOSIM comparing pre-challenge (−72 to 0 h) samples 
to control and ceftiofur samples after cessation of treatment (156 to 216 h) (d). For comparison 
and plotting purposes, time points were discretized into categories. 
Unassigned 
Enterobacteriaceae 
Ruminococcaceae 
Planococcaceae 
Aerococcaceae 
Pre-Challenge (-72 to 0h) 
Control (6 to 48h) 
Control (54 to 150h) 
Control (156 to 216h) 
Ceftiofur (6 to 48h) 
Ceftiofur (54 to 150h) 
Ceftiofur (156 to 216h) 
a 
b c 
d 
PC1 (58.55%) 
PC2 (7.43%) 
ANOSIM 
R = 0.132 
P = 0.001 
PC3 (4.09%) 
PC2 (6.15%) 
PC3 (5.12%) PC1 (60.42%) 
ANOSIM 
R = 0.02 
P = 0.305 
ANOSIM 
R = 0.066 
P = 0.057 
PC2 (9.54%) 
PC1 (60.61%) 
PC2 (15.09%) 
ANOSIM 
R = 0.005 
P = 0.415 
PC3 (5.24%) 
PC3 (9.38%) PC1 (20.36%) 
151 
 
 
DISCUSSION 
We have used an in-vivo experimental model of bovine mastitis and state-of-the-art 
technology to describe in detail the dynamic changes that the milk microbiome undergoes upon 
infection, treatment, and resolution of mastitis. To the best of our knowledge, this is the first 
study to investigate an experimental challenge of bovine mastitis using next generation 
sequencing, and the first investigation on the effects of third generation cephalosporins on the 
endogenous microbiota of healthy milk. Here we show that extended intramammary treatment 
with ceftiofur has no effect on the microbiome of milk from E. coli induced mastitis. Using 
multivariate analysis of weighted UniFrac distances and ANOSIM, we demonstrate that the milk 
microbiome returns to a similar state of that of unchallenged quarters 9 days after experimental 
intramammary infection with E. coli, regardless of receiving antimicrobial therapy. Our results 
show a significant decrease on the LogCFUs recovered from milk samples in challenged and 
treated quarters; however no beneficial effect of antimicrobial treatment was observed in somatic 
cell count, rate of decrease of Enterobacteriaceae, or microbial diversity in quarters challenged 
with E. coli. 
We observed a dramatic decrease in microbial diversity following the experimental 
challenge with 100 CFU of E. coli. Other studies that investigated infections in both human 
(Fernandez et al., 2013) and bovine milk (Bhatt et al., 2012, Oikonomou et al., 2012, Oikonomou 
et al., 2014) have also reported that reduced microbial diversity was associated with mastitis. 
Interestingly, we observe here that diversity indexes of challenged quarters returned to indexes 
comparable to uninfected quarters by the end of the study period. This is similar to results 
observed by our group in a study that investigated the microbiome of animals naturally infected 
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with mastitis (Ganda et al., 2016). Treatment of challenged quarters with ceftiofur significantly 
decreased LogCFUs; however this effect could only be observed during treatment 
administration, with no significant differences in LogCFUs detected 12 hours after the last 
intramammary infusion (156h post-challenge). These findings are in agreement with our 
previous study (Ganda et al., 2016) that investigated the effect of ceftiofur in animals naturally 
infected with mastitis. In that study we were able to identify a significant reduction in bacterial 
load of treated animals as measured through number of 16S rRNA copies during treatment 
administration; on the other hand we failed to identify any differences in bacterial load after 
cessation of treatment. Despite the significant drop in LogCFUs observed in treated challenged 
quarters, we could not identify a treatment effect in the relative abundance of 
Enterobacteriaceae. Taking in consideration the significant reduction in live bacteria detected in 
the present study, it is possible that the relative abundance of bacteria remains unchanged but 
treatment with ceftiofur has an effect in impairing the viability of bacteria exposed to the 
antimicrobials. 
Herein we were unable to recognize a treatment effect neither on the rate of change of 
Enterobacteriaceae nor in the overall microbial profile of challenged quarters. These findings 
are in agreement with our previous work (Ganda et al., 2016), in which no significant differences 
were observed in the rate of decrease of Enterobacteriaceae in animals naturally infected with E. 
coli. Moreover, we failed to identify a significant effect of treatment on the total milk 
microbiome as measured by ANOSIM, which is in line with results from our earlier 
investigation. Several studies have investigated the effect of ceftiofur in food animals (Chambers 
et al., 2015, Fleury et al., 2015, Baron et al., 2016); however these studies evaluated parenteral or 
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oral administration of ceftiofur in different microbiome niches, such as the gut. To the best of our 
knowledge, our group is the first to evaluate the effect of intramammary ceftiofur in bovine milk. 
The effect of chemotherapy in human milk microbiome and metabolome has been previously 
reported (Urbaniak et al., 2014). In bovine milk, modifications in the metabolome have also been 
described after the use of parenteral enrofloxacin (Junza et al., 2016). The evidence of ceftiofur-
induced modifications in the microbiome of food animals and the indication of possible drug-
induced changes in milk prompt further investigation to simultaneously characterize the effects 
of cephalosporins in the mammary gland microbiome, metabolome, and resistome. It is possible 
that the observed lack of change in the relative abundance could be accompanied by differences 
in the metabolic profile of bacteria exposed to antimicrobials. Using technologies such as 
shotgun metagenomics, metabolomics, and proteomics (Addis et al., 2016), we could detect 
differences not evident by 16S rRNA sequencing, and conclusions about the effects of 
cephalosporins in the diseased mammary gland may change. 
In our study we observed a dramatic change on the milk microbial profile upon infection 
with E. coli. Nevertheless, the most remarkable result of this investigation was the lack of 
discrimination between the microbiome of pre-challenge samples and the microbiome of milk 
samples from the same quarters collected after disappearance of clinical signs. Multivariate 
analysis of milk microbiome identified a significant difference when pre challenged samples 
were compared to ones collected in the first two days after challenge (-72 to 0h versus 6 to 48h). 
However we failed to identify any differences between the microbiome of treated and untreated 
quarters during treatment administration (time points 54 to 150h). Interestingly, no difference 
could be observed in the overall microbiome assessed through ANOSIM between groups after 
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treatment cessation, indicating that the milk microbiome is capable of returning to the original 
microbial status. The restoration of the microbiota to a healthy milk profile is in line with the 
findings of our investigation in naturally infected animals, in which no differences on the 
microbiome of healthy quarters and cured quarters could be observed 14 days after diagnosis of 
mastitis. Conversely, work by Falentin et al., (2016) identified long-lasting effects in quarters 
with normal milk that had a history of mastitis and suggested that such effects could be due to 
clinical mastitis and the antimicrobials used for the treatment thereof. Nevertheless, work 
performed by that group consisted of a cross-sectional study, and several components related to 
study design, sample collection, and the pathogens associated with mastitis in those animals 
could contribute for differences in the findings between the two studies. Those authors identified 
high abundance of members of the family Staphylococcaceae, with some samples having as 
much as 30% of staphylococci reads assigned to S. aureus, which is known to have adapted to 
persist in the mammary environment, and attach to the cell lining (Schukken et al., 2011b). 
Regardless of S. aureus and E. coli both being considered major mastitis pathogens, the 
mammary environment is known to be a reservoir of Staphylococcus while E. coli is mainly 
considered an environmental mastitis causing bacteria (Schukken et al., 2011b). 
Antimicrobial infusion in healthy mammary glands did not have a significant effect in the 
microbial profile. This was an interesting finding, given that alterations in the flora of healthy 
individuals exposed to antimicrobials favoring the blooming of pathogenic bacteria have been 
described (Theriot et al., 2014). Previous reports of mastitis outbreaks following ‘blitz’ therapy 
(Bradley and Green, 1997), which consists in intramammary treatment of all lactating animals in 
the herd for elimination of a contagious pathogen, led us to hypothesize that shifts in the 
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microbiome of healthy milk would occur in consequence to antimicrobial exposure, as it has 
been observed in other niches (Theriot et al., 2014, Chambers et al., 2015). Nevertheless, 
intriguing work by Zaura and colleagues (2015) have reported a surprising resilience of the 
salivary microbiome upon exposure to different antimicrobials. While authors of the latter study 
observed significant and long-lasting changes in the fecal microbiome, the microbiome of the 
saliva presented only short-term ecological consequences, representing two radically different 
responses in two niches of the same individuals. It is possible that the microbiome of the 
mammary gland present itself as stable and resilient, comparable to what was observed in the 
salivary microbiome. This hypothesis is corroborated by the highly diverse microbiome of 
healthy milk described in many studies (Cabrera-Rubio et al., 2012, Addis et al., 2016, 
Fitzstevens et al., 2016). One could also speculate that the healthy milk microbiome does not 
contain strains of bacteria that are resistant to ceftiofur and capable of taking advantage due to 
the lack of competition imposed by antimicrobial exposure. On the contrary of what is observed 
in the gut, the very low bacterial load in healthy milk reported in our former study might indicate 
that the milk microbial environment is not as competitive, and is less favorable to the overgrowth 
of bacteria and subsequent change in the microbial profile.  
In this study, three out of the twelve challenged cows did not develop an infection 
following the challenge with E. coli. Several factors could account for this occurrence, most 
importantly the fact that these animals had significantly higher SCC in the time points prior to 
experimental infection. This finding is in agreement with Schukken (2011) and Burvenich (2003) 
which have reported that the success of any intramammary infection is dependent upon the stage 
of lactation and the initial amount of milk leukocytes. In addition, our data follows the reasoning 
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of Burvenich (2003), which stated that the severity and outcome of E. coli mastitis are cow-
dependent, rather than entirely pathogen-dependent; however, it is important to highlight that in 
our study we have evaluated infection with a single characterized strain of E. coli. The dynamics 
of E. coli associated mastitis and its resolution are multifactorial, involving aspects of the 
animal’s immune system, and features of the pathogen involved (Richards et al., 2015, Keane, 
2016). Due to the anatomic structure of the udder, it is generally assumed that infection in one 
quarter should not affect the immune status of neighboring quarters. Recent studies have 
contested this hypothesis, providing evidence of interdependence between infected and healthy 
quarters (Merle et al., 2007, Blagitz et al., 2015). Jensen and colleagues (2013) have evaluated 
the transcriptional response of uninfected quarters in animals challenged with two major mastitis 
pathogens, and described that the response in non-affected quarters was greater in animals with 
E. coli associated mastitis. Although other immune parameters were not evaluated in the current 
study, the numerical increase in somatic cell count in unchallenged quarters after intramammary 
infection with E. coli observed here is in agreement with Jansen et al., (2013) and Blagitz et al., 
(2015), indicating that the immune response in the mammary gland is to some extent influenced 
by the status of adjacent quarters. 
CONCLUSION 
We have demonstrated here that the bovine mammary gland harbors a resilient 
microbiome, capable of reestablishing itself after dramatic changes due to an infectious event 
with an environmental pathogen. While all cows were inoculated with the same bacterial load, 
unique responses were observed in different animals. No differences were observed in the 
microbial profile of unchallenged mammary glands that were exposed to extended 
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intramammary antimicrobial therapy. The milk microbiome was shown to be diverse and stable, 
indicating that bacteria within the mammary gland are tightly regulated. Our results corroborate 
for judicious use of antimicrobials in the dairy industry, demonstrating that due to the resilience 
of the mammary gland microbiome, certain cases of mastitis are capable of resolving 
independently of the use of intramammary antimicrobials.  
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SUPPLEMENTARY INFORMATION  
Figure 5.S1. Description of the microbiome from different quarters over time on animal A.  
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Figure 5.S2. Description of the microbiome from different quarters over time on animal B. 
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Figure 5.S3. Description of the microbiome from different quarters over time on animal C. 
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Figure 5.S4. Description of the microbiome from different quarters over time on animal D. 
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Figure 5.S5. Description of the microbiome from different quarters over time on animal E. 
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Figure 5.S6. Description of the microbiome from different quarters over time on animal F. 
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Figure 5.S7. Description of the microbiome from different quarters over time on animal G. 
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Figure 5.S8. Description of the microbiome from different quarters over time on animal H. 
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Figure 5.S9. Description of the microbiome from different quarters over time on animal I. 
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Figure 5.S10. Description of the microbiome from different quarters over time on animal J. 
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Figure 5.S11. Description of the microbiome from different quarters over time on animal K. 
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Figure 5.S12. Description of the microbiome from different quarters over time on animal L. 
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CHAPTER 6 
CONCLUSION AND FUTURE DIRECTIONS 
The overall objective of the research conducted here is to provide data that can facilitate 
effective management, treatment, and understanding of bovine mastitis. In chapter two, we 
conclude that the diagnostic system evaluated is suitable for use under field conditions, 
presenting overall sensitivity and specificity of 83% and 92% compared with results from 
standard laboratory diagnosis. Accumast® represents a unique approach for on-farm 
identification of bacteria present in milk, through the straightforward color-based interpretation. 
Through the use of this tool, diagnosis of mastitis pathogens can be performed by individuals 
with limited microbiology training, which facilitates selective antimicrobial therapy of mastitic 
cows. 
While investigating the potential of injectable trace mineral supplementation to improve 
udder health, we identified that animals cured from subclinical mastitis had higher 
concentrations of phosphorus and selenium, irrespective of receiving or not supplementation. 
Furthermore, trace mineral supplementation tended to improve subclinical mastitis cure in cows 
with three or more lactations. Nevertheless, no overall effect was observed in reducing the 
incidence of clinical mastitis; however mineral supplementation significantly reduced the 
incidence of chronic clinical mastitis in primiparous animals. Further research is necessary to 
separate the effects of injectable supplementation of trace minerals and the mineral profile in 
cured animals. Supplementation with trace minerals did not affect somatic cell count, milk yield, 
or milk composition. 
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The findings from both chapters four and five indicate that the milk harbors a resilient 
microbiome, and that the antimicrobial treatment of mild and moderate cases of bovine mastitis 
caused by Escherichia coli or yielding negative results upon aerobic culture is not advantageous. 
The research methods employed during these studies contribute to a better understanding of the 
microbial dynamics of bovine mastitis. Intramammary infusion of E. coli severely affected 
microbial diversity as well as significantly increased levels of Enterobacteriaceae. Ceftiofur had 
a significant effect in decreasing bacterial load in both studies, however this effect could only be 
observed during treatment administration. Nevertheless, the most remarkable result was the lack 
of difference in microbial profile, pathogen load, pathogen clearance and diversity between 
treated and untreated quarters after treatment cessation. We learn from these studies that 
judicious use of antimicrobial can be achieved without long term changes in the milk 
microbiome and without compromising animal health. 
Nevertheless, several avenues of research remain open in this topic. For instance, we 
identified through the significant reduction in LogCFU that intramammary treatment with 
ceftiofur impairs the viability of E. coli without affecting the relative abundance of 
Enterobacteriaceae. To date, no data is available regarding possible changes that can occur in 
the metabolic and transcriptional profile of bacteria present in milk exposed to antimicrobial 
agents. It is important to highlight that although a vast amount of information is provided in this 
dissertation we have focused in specific mastitis pathogens, and have only evaluated the effects 
of one antimicrobial on the milk microbiome. The etiology of bovine mastitis is complex, and 
several classes of antimicrobials are currently labeled for intramammary treatment of mastitis. 
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Based on the research carried out here we cannot predict what would be the changes in the 
microbial profile when other pathogens and other drugs come into play. 
It will be interesting to assess how active are the microbes present in milk. Through 
sequencing the 16S rRNA we are able to identify which organisms are present in milk, but it is 
not possible to assess the viability of such organisms. Moreover, no conclusions can be drawn 
from the studies presented here in regards of increase in antimicrobial resistance.  
In conclusion, further research using other ‘omics’ technologies such as metabolomics 
and proteomics will have the ability to detect differences and treatment effects that are not 
evident by microbiome profiling through sequencing of the 16S fraction of ribosomal RNA.  
